

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

CA00/258

09/936271

PCT / CA 00 / 00258

87

E

2000 (27.06.00)

PA 232822

REC'D 11 JUL 2000

WIPO

PCT

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

4

United States Patent and Trademark Office

April 10, 2000

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/127,386

FILING DATE: April 01, 1999

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

P. SWAIN

Certifying Officer

A/PROV

04/01/99

10544 U.S. PTO  
11757.30USP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10544 U.S. PTO  
60/127386  
04/01/99

CERTIFICATE UNDER 37 CFR 1.10  
Express Mail mailing label number: EL119855211US  
Date of Deposit: April 1, 1999  
I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.  
By: Walter White  
Name: Walter White

REQUEST FOR PROVISIONAL APPLICATION UNDER 37 C.F.R. § 1.53(c)

BOX PROVISIONAL PATENT APPLICATION  
Assistant Commissioner for Patents  
Washington, DC 20231

Dear Sir:

This is a request for filing a Provisional application for patent under 37 CFR § 1.53(c) entitled NOVEL HUMAN KALLIKREIN-LIKE GENES by the following inventor(s):

Full Name Of Inventor	Family Name YOUSEF	First Given Name George	Second Given Name M.
Residence & Citizenship	City Toronto	State or Foreign Country Ontario Canada	Country of Citizenship Egypt
Post Office Address	Post Office Address 90 Gerrard St. West, Apt. 1402	City Toronto	State & Zip Code/Country Ontario M5G 1J6 Canada
Full Name Of Inventor	Family Name LUO	First Given Name Liu-Ying	Second Given Name
Residence & Citizenship	City Toronto	State or Foreign Country Ontario Canada	Country of Citizenship China
Post Office Address	Post Office Address 222 Elm St., Apt. 1518	City Toronto	State & Zip Code/Country Ontario M5T 1K5 Canada
Full Name Of Inventor	Family Name Diamandis	First Given Name Eleftherios	Second Given Name P.
Residence & Citizenship	City Toronto	State or Foreign Country Ontario, Canada	Country of Citizenship Canada
Post Office Address	Post Office Address 44 Gerrard St. West, Suite 1504	City Toronto	State & Zip Code/Country Ontario M5G 2K2 Canada

- ☒ Enclosed is the Provisional application for patent as follows: 42 pages of specification, and 16 sheets of drawings.
- ☒ A Verified Statement that this filing is by a small entity (37 CFR 1.9, 1.27, 1.28) is attached.
- ☒ Payment of Provisional filing fee under 37 C.F.R. § 1.16(k):  
☒ Attached is a check in the amount of \$ 75.00.  
☐ Please charge Deposit Account No. 13-2725.  
☐ PAYMENT OF THE FILING FEE IS BEING DEFERRED.
- ☒ The Commissioner is hereby authorized to charge any additional fees as set forth in 37 CFR §§ 1.16 to 1.18 which may be required by this paper or credit any overpayment to Account No. 13-2725.

5. ☐ Enclosed is an Assignment of the invention to \_\_\_\_\_, Recordation Form Cover Sheet and a check for \$ \_\_\_\_\_ to cover the Recordation Fee.
6. ☐ Also Enclosed:
7. ☐ The invention was made by the following agency of the United States Government or under a contract with the following agency of the United States Government:
8. ☒ Address all future communications to the Attention of Douglas P. Mueller (may only be completed by attorney or agent of record) at the address below.
9. ☒ A return postcard is enclosed.


Respectfully submitted,

YOUSEF et al.

By their Attorneys,

MERCHANT, GOULD, SMITH, EDELL,  
WELTER & SCHMIDT, P.A.  
3100 Norwest Center  
90 South Seventh Street  
Minneapolis, Minnesota 55402  
(612) 332-5300

By

  
Douglas P. Mueller  
Reg No. 30,300  
DPM:vvh

Dated: April 1, 1999

60127286-010499

MSH File : KALLIKREIN

**TITLE:** Novel Human Kallikrein-Like Genes

**FIELD OF THE INVENTION**

The invention relates to nucleic acid molecules, proteins encoded by such nucleic acid  
5 molecules; and use of the proteins and nucleic acid molecules.

**BACKGROUND OF THE INVENTION**

Kallikreins and kallikrein-like proteins are a subgroup of the serine protease enzyme  
family and exhibit a high degree of substrate specificity (1). The biological role of these  
kallikreins is the selective cleavage of specific polypeptide precursors (substrates) to release  
10 peptides with potent biological activity (2). In mouse and rat, kallikreins are encoded by large  
multigene families. In the mouse genome, at least 24 genes have been identified (3). Expression  
of 11 of these genes has been confirmed; the rest are presumed to be pseudogenes (4). A similar  
family of 15-20 kallikreins has been found in the rat genome (5) where at least 4 of these are  
known to be expressed (6).

15 Three human kallikrein genes have been described, i.e. prostatic specific antigen (PSA  
or KLK3) (7), human glandular kallikrein (KLK2) (8) and tissue (pancreatic-renal) kallikrein  
(KLK1) (9). The PSA gene spans 5.8 Kb of sequence which has been published (7); the KLK2  
gene has a size of 5.2 Kb and its complete structure has also been elucidated (8). The KLK1  
gene is approximately 4.5 Kb long and the exon sequences and the exon/intron junctions of this  
20 gene have been determined (9).

The mouse kallikrein genes are clustered in groups of up to 11 genes on chromosome  
7 and the distance between the genes in the various clusters can be as small as 3-7 Kb (3). All  
three human kallikrein genes have been assigned to chromosome 19q13.2 - 19q13.4 and the  
distance between PSA and KLK2 has been estimated to be 12 Kb (9).

25 A major difference between mouse and human kallikreins is that two of the human  
kallikreins (KLK2 and KLK3) are expressed almost exclusively in the prostate while in animals  
none of the kallikreins is localized in this organ. Other candidate new members of the human  
kallikrein gene family include protease M (10) (also named Zyme (11) or neurosin (12) and the  
normal epithelial cell-specific gene-1 (NES1) (13). Both genes have been assigned to  
30 chromosome 19q13.3 (10,14) and show structural homology with other serine proteases and the  
kallikrein gene family (10-14).

## SUMMARY OF THE INVENTION

In efforts to precisely define the relative genomic location of PSA, KLK2, Zyme and NES1 genes, an area spanning approximately 300 Kb of contiguous sequence on human chromosome 19 (19q13.3-q13.4) was examined. The present inventors were able to identify the relative location of the known kallikrein genes and, in addition, they identified other kallikrein-like genes which exhibit both location proximity and structural similarity with the known members of the human kallikrein family. The novel genes exhibit homology with the currently known members of the kallikrein family and they are co-localized in the same genomic region. These new genes, like the already known kallikreins have utility in various cancers including those of the breast, testicular, and prostate.

The kallikrein-like proteins described herein are individually referred to as "KLK-L1 to KLK-L5", and collectively as "kallikrein-like proteins" or "KLK-L Proteins". The genes encoding the proteins are referred to as *klk-11* to *klk-15* or kallikrein-like genes or "*klk-l* genes".

Broadly stated the present invention relates to an isolated nucleic acid molecule which comprises:

- (i) a nucleic acid sequence encoding a protein having substantial sequence identity preferably at least 60% sequence identity, with an amino acid sequence of KLK-L1 to KLK-L5 as shown in Tables 2 to 6;
- (ii) a nucleic acid sequence encoding a protein comprising with an amino acid sequence of KLK-L1 to KLK-L5 as shown in Tables 2 to 6;
- (iii) nucleic acid sequences complementary to (i);
- (iv) a degenerate form of a nucleic acid sequence of (i);
- (v) a nucleic acid sequence capable of hybridizing under stringent conditions to a nucleic acid sequence in (i), (ii) or (iii);
- (vi) a nucleic acid sequence encoding a truncation, an analog, an allelic or species variation of a protein comprising with an amino acid sequence of KLK-L1 to KLK-L5 as shown in Tables 2 to 6; or
- (vii) a fragment, or allelic or species variation of (i), (ii) or (iii).

Preferably, a purified and isolated nucleic acid molecule of the invention comprises:

- (i) a nucleic acid sequence comprising the sequence of Figure 2, 3, 4, 5, or 6 wherein T can also be U;

- (ii) nucleic acid sequences complementary to (i), preferably complementary to the full nucleic acid sequence of Figure 2, 3, 4, 5, or 6;
- (iii) a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid of (i) or (ii) and preferably having at least 18 nucleotides; or
- 5 (iv) a nucleic acid molecule differing from any of the nucleic acids of (i) to (iii) in codon sequences due to the degeneracy of the genetic code.

The invention also contemplates a nucleic acid molecule comprising a sequence encoding a truncation of a KLK-L protein, an analog, or a homolog of a KLK-L Protein or a truncation thereof. (KLK-L Protein and truncations, analogs and homologs of the KLK-L  
10 Protein are also collectively referred to herein as "KLK-L Related Proteins").

The nucleic acid molecules of the invention may be inserted into an appropriate expression vector, i.e. a vector that contains the necessary elements for the transcription and translation of the inserted coding sequence. Accordingly, recombinant expression vectors adapted for transformation of a host cell may be constructed which comprise a nucleic acid  
15 molecule of the invention and one or more transcription and translation elements linked to the nucleic acid molecule.

The recombinant expression vector can be used to prepare transformed host cells expressing KLK-L Related Proteins. Therefore, the invention further provides host cells containing a recombinant molecule of the invention. The invention also contemplates transgenic  
20 non-human mammals whose germ cells and somatic cells contain a recombinant molecule comprising a nucleic acid molecule of the invention, in particular one which encodes an analog of the KLK-L Protein, or a truncation of the KLK-L Protein.

The invention further provides a method for preparing KLK-L Related Proteins utilizing the purified and isolated nucleic acid molecules of the invention. In an embodiment a method  
25 for preparing a KLK-L Related Protein is provided comprising (a) transferring a recombinant expression vector of the invention into a host cell; (b) selecting transformed host cells from untransformed host cells; (c) culturing a selected transformed host cell under conditions which allow expression of the KLK-L Related Protein; and (d) isolating the KLK-L Related Protein.

The invention further broadly contemplates an isolated KLK-L Protein comprising an  
30 amino acid sequence as shown in Tables 2 to 6.

The KLK-L Related Proteins of the invention may be conjugated with other molecules,

0427766-0404-06



such as proteins, to prepare fusion proteins. This may be accomplished, for example, by the synthesis of N-terminal or C-terminal fusion proteins.

The invention further contemplates antibodies having specificity against an epitope of a KLK-L Related Protein of the invention. Antibodies may be labeled with a detectable  
5 substance and used to detect proteins of the invention in tissues and cells.

The invention also permits the construction of nucleotide probes which are unique to the nucleic acid molecules of the invention and/or to proteins of the invention. Therefore, the invention also relates to a probe comprising a nucleic acid sequence of the invention, or a nucleic acid sequence encoding a protein of the invention, or a part thereof. The probe may be  
10 labeled, for example, with a detectable substance and it may be used to select from a mixture of nucleotide sequences a nucleic acid molecule of the invention including nucleic acid molecules coding for a protein which displays one or more of the properties of a protein of the invention.

The invention still further provides a method for identifying a substance which binds to  
15 a protein of the invention comprising reacting the protein with at least one substance which potentially can bind with the protein, under conditions which permit the formation of complexes between the substance and protein and assaying for complexes, for free substance, or for non-complexed protein. The invention also contemplates methods for identifying substances that bind to other intracellular proteins that interact with a KLK-L Related Protein. Methods can also  
20 be utilized which identify compounds which bind to KLK-L gene regulatory sequences (e.g. promoter sequences).

Still further the invention provides a method for evaluating a compound for its ability to modulate the biological activity of a KLK-L Related Protein of the invention. For example a substance which inhibits or enhances the interaction of the protein and a substance which  
25 binds to the protein may be evaluated. In an embodiment, the method comprises providing a known concentration of a KLK-L Related Protein, with a substance which binds to the protein and a test compound under conditions which permit the formation of complexes between the substance and protein, and removing and/or detecting complexes.

Compounds which modulate the biological activity of a protein of the invention may  
30 also be identified using the methods of the invention by comparing the pattern and level of expression of the protein of the invention in tissues and cells, in the presence, and in the absence

of the compounds.

The substances and compounds identified using the methods of the invention, and peptides of the invention may be used to modulate the biological activity of a KLK-L Related Protein of the invention, and they may be used in the treatment of conditions such as cancer (e.g. breast, testicular, and prostate cancer). Accordingly, the substances and compounds may be formulated into compositions for administration to individuals suffering from cancer.

Therefore, the present invention also relates to a composition comprising one or more of a protein of the invention, a peptide of the invention, or a substance or compound identified using the methods of the invention, and a pharmaceutically acceptable carrier, excipient or diluent. A method for treating or preventing cancer is also provided comprising administering to a patient in need thereof, a KLK-L Related Protein of the invention, or a composition of the invention.

The present inventors have also identified a novel gene homologous to myelin associated protein designated UG. Therefore the invention provides an isolated nucleic acid molecule which comprises:

- (i) a nucleic acid sequence encoding a protein having substantial sequence identity preferably at least 60% sequence identity, with an amino acid sequence as shown in Table 7;
- (ii) a nucleic acid sequence encoding a protein comprising with an amino acid sequence of as shown in Table 7;
- (iii) nucleic acid sequences complementary to (i);
- (iv) a degenerate form of a nucleic acid sequence of (i);
- (v) a nucleic acid sequence capable of hybridizing under stringent conditions to a nucleic acid sequence in (i), (ii) or (iii);
- (vi) a nucleic acid sequence encoding a truncation, an analog, an allelic or species variation of a protein comprising with an amino acid sequence of as shown in Table 7; or
- (vii) a fragment, or allelic or species variation of (i), (ii) or (iii).

The invention further contemplates an isolated UG Protein comprising an amino acid sequence as shown in Table 7.

The general description herein relating to the klk-l nucleic acid molecules and KLK-L

Proteins and KLK-L Related Proteins, antibodies, methods, and compositions are applicable to the novel UG protein and nucleic acid molecule.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

The invention will now be described in relation to the drawings in which:

Figure 1: An approximate 300 Kb of contiguous genomic sequence around chromosome 19q13.3 - q13.4 represented by 8 contigs, each one shown with its length in Kb.

The contig numbers refer to those reported in the Lawrence Livermore National Laboratory website. Note the localization of the seven known genes (PSA, KLK2, Zyme, NES1, HSCCE, neuropsin and TLSP) (see abbreviations for full names of these genes). All genes are represented with arrows denoting the direction of transcription. The gene with no homology to human kallikreins is termed UG (unknown gene). The five new kallikrein-like genes (KLK-L1 to KLK-L5) were numbered from the most centromeric to the most telomeric. Numbers just below or just above the arrows indicate appropriate Kb lengths in each contig. The length of each of these genes may change in the future since not all exons were identified for each new gene, as shown in Tables 2-7.

Figure 2 shows the nucleic acid sequence of KLK-L1;

Figure 3 shows the nucleic acid sequence of KLK-L2;

Figure 4 shows the nucleic acid sequence of KLK-L3;

Figure 5 shows the nucleic acid sequence of KLK-L4; and

Figure 6 shows the nucleic acid sequence of KLK-L5.

#### **DETAILED DESCRIPTION OF THE INVENTION**

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See for example, Sambrook, Fritsch, & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor

Laboratory Press, Cold Spring Harbor, N.Y.); DNA Cloning: A Practical Approach, Volumes I and II (D.N. Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization B.D. Hames & S.J. Higgins eds. (1985); Transcription and Translation B.D. Hames & S.J. Higgins eds (1984); Animal Cell Culture R.I. Freshney, ed. (1986); Immobilized  
5 Cells and enzymes IRL Press, (1986); and B. Perbal, A Practical Guide to Molecular Cloning (1984).

1. **Nucleic Acid Molecules of the Invention**

As hereinbefore mentioned, the invention provides an isolated nucleic acid molecule having a sequence encoding a KLK-L Protein. The term "isolated" refers to a nucleic acid  
10 substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical reactants, or other chemicals when chemically synthesized. An "isolated" nucleic acid may also be free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid molecule) from which the nucleic acid is derived. The term "nucleic acid" is intended to include DNA and RNA and can be either  
15 double stranded or single stranded. In an embodiment, a nucleic acid molecule encodes a KLK-L Protein comprising an amino acid sequence as shown in Tables 2 to 6, preferably a nucleic acid molecule comprising a nucleic acid sequence as shown in Figure 2, 3, 4, 5, or 6.

The invention includes nucleic acid sequences complementary to a nucleic acid encoding a KLK-L Protein comprising an amino acid sequence as shown in Tables 2 to 6, preferably the  
20 nucleic acid sequences complementary to a full nucleic acid sequence shown in Figure 2, 3, 4, 5, or 6.

The invention includes nucleic acid molecules having substantial sequence identity or homology to nucleic acid sequences of the invention or encoding proteins having substantial identity or similarity to the amino acid sequence shown in Tables 2 to 9. Preferably, the nucleic  
25 acids have substantial sequence identity for example at least 40% nucleic acid identity; more preferably 50% nucleic acid identity; and most preferably at least 60% to 80% sequence identity.

"Identity" as known in the art and used herein, is a relationship between two or more amino acid sequences or two or more nucleic acid sequences, as determined by comparing the sequences. It also refers to the degree of sequence relatedness between amino acid or nucleic  
30 acid sequences, as the case may be, as determined by the match between strings of such sequences. Identity and similarity are well known terms to skilled artisans and they can be

calculated by conventional methods (for example see Computational Molecular Biology, Lesk, A.M. ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W. ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M. and Griffin, H.G. eds., Humana Press, New Jersey, 1994; Sequence  
5 Analysis in Molecular Biology, von Heinje, G. Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J. eds. M. Stockton Press, New York, 1991, Carillo, H. and Lipman, D., SIAM J. Applied Math. 48:1073, 1988). Methods which are designed to give the largest match between the sequences are generally preferred. Methods to determine identity and similarity are codified in publicly available computer programs including the GCG program  
10 package (Devereux J. et al., Nucleic Acids Research 12(1): 387, 1984); BLASTP, BLASTN, and FASTA (Atschul, S.F. et al. J. Molec. Biol. 215: 403-410, 1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al. NCBI  
NLM NIH Bethesda, Md. 20894; Altschul, S. et al. J. Mol. Biol. 215: 403-410, 1990).

Isolated nucleic acid molecules encoding a KLK-L Protein, and having a sequence which  
15 differs from a nucleic acid sequence of the invention due to degeneracy in the genetic code are also within the scope of the invention. Such nucleic acids encode functionally equivalent proteins (e.g., a KLK-L Protein) but differ in sequence from the sequence of a KLK-L Protein due to degeneracy in the genetic code. As one example, DNA sequence polymorphisms within the nucleotide sequence of a KLK-L Protein may result in silent mutations which do not affect  
20 the amino acid sequence. Variations in one or more nucleotides may exist among individuals within a population due to natural allelic variation. Any and all such nucleic acid variations are within the scope of the invention. DNA sequence polymorphisms may also occur which lead to changes in the amino acid sequence of a KLK-L Protein. These amino acid polymorphisms are also within the scope of the present invention.

25 Another aspect of the invention provides a nucleic acid molecule which hybridizes under stringent conditions, preferably high stringency conditions to a nucleic acid molecule which comprises a sequence which encodes a KLK-L Protein having an amino acid sequence shown in Tables 2 to 6. Appropriate stringency conditions which promote DNA hybridization are known to those skilled in the art, or can be found in Current Protocols in Molecular Biology,  
30 John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C may be employed. The

stringency may be selected based on the conditions used in the wash step. By way of example, the salt concentration in the wash step can be selected from a high stringency of about  $0.2 \times \text{SSC}$  at  $50^{\circ}\text{C}$ . In addition, the temperature in the wash step can be at high stringency conditions, at about  $65^{\circ}\text{C}$ .

5        It will be appreciated that the invention includes nucleic acid molecules encoding a KLK-L Related Protein including truncations of a KLK-L Protein, and analogs of a KLK-L Protein as described herein. It will further be appreciated that variant forms of the nucleic acid molecules of the invention which arise by alternative splicing of an mRNA corresponding to a cDNA of the invention are encompassed by the invention.

10        An isolated nucleic acid molecule of the invention which comprises DNA can be isolated by preparing a labelled nucleic acid probe based on all or part of a nucleic acid sequence of the invention. The labeled nucleic acid probe is used to screen an appropriate DNA library (e.g. a cDNA or genomic DNA library). For example, a cDNA library can be used to isolate a cDNA encoding a KLK-L Related Protein by screening the library with the labeled  
15        probe using standard techniques. Alternatively, a genomic DNA library can be similarly screened to isolate a genomic clone encompassing a gene encoding a KLK-L Related Protein. Nucleic acids isolated by screening of a cDNA or genomic DNA library can be sequenced by standard techniques.

20        An isolated nucleic acid molecule of the invention which is DNA can also be isolated by selectively amplifying a nucleic acid encoding a KLK-L Related Protein using the polymerase chain reaction (PCR) methods and cDNA or genomic DNA. It is possible to design synthetic oligonucleotide primers from the nucleotide sequence of the invention for use in PCR. A nucleic acid can be amplified from cDNA or genomic DNA using these oligonucleotide primers and standard PCR amplification techniques. The nucleic acid so amplified can be  
25        cloned into an appropriate vector and characterized by DNA sequence analysis. cDNA may be prepared from mRNA, by isolating total cellular mRNA by a variety of techniques, for example, by using the guanidinium-thiocyanate extraction procedure of Chirgwin et al., Biochemistry, 18, 5294-5299 (1979). cDNA is then synthesized from the mRNA using reverse transcriptase (for example, Moloney MLV reverse transcriptase available from Gibco/BRL, Bethesda, MD, or  
30        AMV reverse transcriptase available from Seikagaku America, Inc., St. Petersburg, FL)...

      An isolated nucleic acid molecule of the invention which is RNA can be isolated by

cloning a cDNA encoding a KLK-L Related Protein into an appropriate vector which allows for transcription of the cDNA to produce an RNA molecule which encodes a KLK-L Related Protein. For example, a cDNA can be cloned downstream of a bacteriophage promoter, (e.g. a T7 promoter) in a vector, cDNA can be transcribed *in vitro* with T7 polymerase, and the resultant RNA can be isolated by conventional techniques.

Nucleic acid molecules of the invention may be chemically synthesized using standard techniques. Methods of chemically synthesizing polydeoxynucleotides are known, including but not limited to solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See e.g., Itakura et al. U.S. Patent No. 4,598,049; Caruthers et al. U.S. Patent No. 4,458,066; and Itakura U.S. Patent Nos. 4,401,796 and 4,373,071).

Determination of whether a particular nucleic acid molecule encodes a KLK-L Related Protein can be accomplished by expressing the cDNA in an appropriate host cell by standard techniques, and testing the expressed protein in the methods described herein. A cDNA encoding a KLK-L Related Protein can be sequenced by standard techniques, such as dideoxynucleotide chain termination or Maxam-Gilbert chemical sequencing, to determine the nucleic acid sequence and the predicted amino acid sequence of the encoded protein.

The initiation codon and untranslated sequences of a KLK-L Related Protein may be determined using computer software designed for the purpose, such as PC/Gene (IntelliGenetics Inc., Calif.). The intron-exon structure and the transcription regulatory sequences of a gene encoding a KLK-L Related Protein may be confirmed by using a nucleic acid molecule of the invention encoding a KLK-L Related Protein to probe a genomic DNA clone library. Regulatory elements can be identified using standard techniques. The function of the elements can be confirmed by using these elements to express a reporter gene such as the lacZ gene which is operatively linked to the elements. These constructs may be introduced into cultured cells using conventional procedures or into non-human transgenic animal models. In addition to identifying regulatory elements in DNA, such constructs may also be used to identify nuclear proteins interacting with the elements, using techniques known in the art.

In a particular embodiment of the invention, the nucleic acid molecules isolated using the methods described herein are mutant *KLK-L* gene alleles. The mutant alleles may be isolated from individuals either known or proposed to have a genotype which contributes to the

symptoms of cancer (e.g. breast, testicular, or prostate cancer). Mutant alleles and mutant allele products may be used in therapeutic and diagnostic methods described herein. For example, a cDNA of a mutant *KLK-L* gene may be isolated using PCR as described herein, and the DNA sequence of the mutant allele may be compared to the normal allele to ascertain the mutation(s)

5 responsible for the loss or alteration of function of the mutant gene product. A genomic library can also be constructed using DNA from an individual suspected of or known to carry a mutant allele, or a cDNA library can be constructed using RNA from tissue known or suspected to express the mutant allele. A nucleic acid encoding a normal *KLK-L* gene or any suitable fragment thereof, may then be labeled and used as a probe to identify the corresponding mutant  
10 allele in such libraries. Clones containing mutant sequences can be purified and subjected to sequence analysis. In addition, an expression library can be constructed using cDNA from RNA isolated from a tissue of an individual known or suspected to express a mutant *KLK-L* allele. Gene products made by the putatively mutant tissue may be expressed and screened, for example using antibodies specific for a *KLK-L* Related Protein as described herein. Library  
15 clones identified using the antibodies can be purified and subjected to sequence analysis.

The sequence of a nucleic acid molecule of the invention, or a fragment of the molecule, may be inverted relative to its normal presentation for transcription to produce an antisense nucleic acid molecule. An antisense nucleic acid molecule may be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.

20 **2. Proteins of the Invention**

An amino acid sequence of a *KLK-L* Protein comprises a sequence as shown in Tables 2 to 6.

In addition to proteins comprising an amino acid sequence as shown Tables 2 to 6 the proteins of the present invention include truncations of a *KLK-L* Protein, analogs of a *KLK-L*  
25 Protein, and proteins having sequence identity or similarity to a *KLK-L* Protein, and truncations thereof as described herein (i.e. *KLK-L* Related Proteins). Truncated proteins may comprise peptides of between 3 and 70 amino acid residues, ranging in size from a tripeptide to a 70 mer polypeptide.

The truncated proteins may have an amino group (-NH<sub>2</sub>), a hydrophobic group (for  
30 example, carbobenzoxy, dansyl, or T-butyloxycarbonyl); an acetyl group, a 9-fluorenylmethoxy-carbonyl (PMOC) group, or a macromolecule including, but not limited to



lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates at the amino terminal end. The truncated proteins may have a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecule including but not limited to lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates at the carboxy terminal end.

5           The proteins of the invention may also include analogs of a KLK-L Protein, and/or truncations thereof as described herein, which may include, but are not limited to a KLK-L Protein, containing one or more amino acid substitutions, insertions, and/or deletions. Amino acid substitutions may be of a conserved or non-conserved nature. Conserved amino acid substitutions involve replacing one or more amino acids of a KLK-L Protein amino acid  
10           sequence with amino acids of similar charge, size, and/or hydrophobicity characteristics. When only conserved substitutions are made the resulting analog is preferably functionally equivalent to a KLK-L Protein. Non-conserved substitutions involve replacing one or more amino acids of the KLK-L Protein amino acid sequence with one or more amino acids which possess dissimilar charge, size, and/or hydrophobicity characteristics.

15           One or more amino acid insertions may be introduced into a KLK-L Protein. Amino acid insertions may consist of single amino acid residues or sequential amino acids ranging from 2 to 15 amino acids in length.

Deletions may consist of the removal of one or more amino acids, or discrete portions from a KLK-L Protein sequence. The deleted amino acids may or may not be contiguous. The  
20           lower limit length of the resulting analog with a deletion mutation is about 10 amino acids, preferably 20 to 40 amino acids.

The proteins of the invention include proteins with sequence identity or similarity to a KLK-L Protein and/or truncations thereof as described herein. Such KLK-L Proteins include proteins whose amino acid sequences are comprised of the amino acid sequences of KLK-L  
25           Protein regions from other species that hybridize under selected hybridization conditions (see discussion of stringent hybridization conditions herein) with a probe used to obtain a KLK-L Protein. These proteins will generally have the same regions which are characteristic of a KLK-L Protein. Preferably a protein will have substantial sequence identity for example, about 50% identity, preferably 70 to 80% identity, more preferably at least 90% to 95% identity, and most  
30           preferably 98% identity with an amino acid sequence shown in Tables 2 to 6.

A percent amino acid sequence homology, similarity or identity is calculated as the

percentage of aligned amino acids that match the reference sequence using known methods as described herein.

The invention also contemplates isoforms of the proteins of the invention. An isoform contains the same number and kinds of amino acids as a protein of the invention, but the isoform has a different molecular structure. Isoforms contemplated by the present invention preferably have the same properties as a protein of the invention as described herein.

The present invention also includes KLK-L Related Proteins conjugated with a selected protein, or a marker protein (see below) to produce fusion proteins. Additionally, immunogenic portions of a KLK-L Protein and a KLK-L Protein Related Protein are within the scope of the invention.

A KLK-L Related Protein of the invention may be prepared using recombinant DNA methods. Accordingly, the nucleic acid molecules of the present invention having a sequence which encodes a KLK-L Related Protein of the invention may be incorporated in a known manner into an appropriate expression vector which ensures good expression of the protein. Possible expression vectors include but are not limited to cosmids, plasmids, or modified viruses (e.g. replication defective retroviruses, adenoviruses and adeno-associated viruses), so long as the vector is compatible with the host cell used.

The invention therefore contemplates a recombinant expression vector of the invention containing a nucleic acid molecule of the invention, and the necessary regulatory sequences for the transcription and translation of the inserted protein sequence. Suitable regulatory sequences may be derived from a variety of sources, including bacterial, fungal, viral, mammalian, or insect genes (For example, see the regulatory sequences described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Selection of appropriate regulatory sequences is dependent on the host cell chosen as discussed below, and may be readily accomplished by one of ordinary skill in the art. The necessary regulatory sequences may be supplied by the native KLK-L Protein and/or its flanking regions.

The invention further provides a recombinant expression vector comprising a DNA nucleic acid molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is linked to a regulatory sequence in a manner which allows for expression, by transcription of the DNA molecule, of an RNA molecule which is antisense to the nucleic acid sequence of a protein of the invention or a fragment thereof.

Regulatory sequences linked to the antisense nucleic acid can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance a viral promoter and/or enhancer, or regulatory sequences can be chosen which direct tissue or cell type specific expression of antisense RNA.

5       The recombinant expression vectors of the invention may also contain a marker gene which facilitates the selection of host cells transformed or transfected with a recombinant molecule of the invention. Examples of marker genes are genes encoding a protein such as G418 and hygromycin which confer resistance to certain drugs,  $\beta$ -galactosidase, chloramphenicol acetyltransferase, firefly luciferase, or an immunoglobulin or portion thereof such as the Fc  
10       portion of an immunoglobulin preferably IgG. The markers can be introduced on a separate vector from the nucleic acid of interest.

20       The recombinant expression vectors may also contain genes which encode a fusion moiety which provides increased expression of the recombinant protein; increased solubility of the recombinant protein; and aid in the purification of the target recombinant protein by acting  
15       as a ligand in affinity purification. For example, a proteolytic cleavage site may be added to the target recombinant protein to allow separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST),  
20       maltose E binding protein, or protein A, respectively, to the recombinant protein.

25       The recombinant expression vectors may be introduced into host cells to produce a transformant host cell. "Transformant host cells" include host cells which have been transformed or transfected with a recombinant expression vector of the invention. The terms "transformed with", "transfected with", "transformation" and "transfection" encompass the introduction of a  
30       nucleic acid (e.g. a vector) into a cell by one of many standard techniques. Prokaryotic cells can be transformed with a nucleic acid by, for example, electroporation or calcium-chloride mediated transformation. A nucleic acid can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofectin, electroporation or microinjection. Suitable methods  
30       for transforming and transfecting host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other

laboratory textbooks.

Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells. For example, the proteins of the invention may be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus), yeast cells or mammalian cells. Other suitable host cells can be found in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1991).

A host cell may also be chosen which modulates the expression of an inserted nucleic acid sequence, or modifies (e.g. glycosylation or phosphorylation) and processes (e.g. cleaves) the protein in a desired fashion. Host systems or cell lines may be selected which have specific and characteristic mechanisms for post-translational processing and modification of proteins. For example, eukaryotic host cells including CHO, VERO, BHK, HeLA, COS, MDCK, 293, 3T3, and WI38 may be used. For long-term high-yield stable expression of the protein, cell lines and host systems which stably express the gene product may be engineered.

Host cells and in particular cell lines produced using the methods described herein may be particularly useful in screening and evaluating compounds that modulate the activity of a KLK-L Related Protein.

The proteins of the invention may also be expressed in non-human transgenic animals including but not limited to mice, rats, rabbits, guinea pigs, micro-pigs, goats, sheep, pigs, non-human primates (e.g. baboons, monkeys, and chimpanzees) [see-Hammer et al. (Nature 315:680-683, 1985), Palmiter et al. (Science-222:809-814, 1983), Brinster et al. (Proc Natl. Acad. Sci-USA, 82:4438-4442, 1985), Palmiter and Brinster (Cell. 41:343-345, 1985) and U.S. Patent No. 4,736,866]. Procedures known in the art may be used to introduce a nucleic acid molecule of the invention encoding a KLK-L Related Protein into animals to produce the founder lines of transgenic animals. Such procedures include pronuclear microinjection, retrovirus mediated gene transfer into germ lines, gene targeting in embryonic stem cells, electroporation of embryos, and sperm-mediated gene transfer.

The present invention contemplates a transgenic animal that carries the *KLK-L* gene in all their cells, and animals which carry the transgene in some but not all their cells. The transgene may be integrated as a single transgene or in concatamers. The transgene may be selectively introduced into and activated in specific cell types (See-for example, Lasko et al, 1992 Proc. Natl. Acad. Sci. USA 89: 6236). The transgene may be integrated into the

chromosomal site of the endogenous gene by gene targeting. The transgene may be selectively introduced into a particular cell type inactivating the endogenous gene in that cell type (See Gu et al Science 265: 103-106).

5 The expression of a recombinant KLK-L Related Protein in a transgenic animal may be assayed using standard techniques. Initial screening may be conducted by Southern Blot analysis, or PCR methods to analyze whether the transgene has been integrated. The level of mRNA expression in the tissues of transgenic animals may also be assessed using techniques including Northern blot analysis of tissue samples, *in situ* hybridization, and RT-PCR. Tissue may also be evaluated immunocytochemically using antibodies against KLK-L Protein.

10 Proteins of the invention may also be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964, J. Am. Chem. Assoc. 85:2149-2154) or synthesis in homogenous solution (Houbenweyl, 1987, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).

15 N-terminal or C-terminal fusion proteins comprising a KLK-L Related Protein of the invention conjugated with other molecules, such as proteins, may be prepared by fusing, through recombinant techniques, the N-terminal or C-terminal of a KLK-L Related Protein, and the sequence of a selected protein or marker protein with a desired biological function. The resultant fusion proteins contain KLK-L Protein fused to the selected protein or marker protein as described herein. Examples of proteins which may be used to prepare fusion proteins include  
20 immunoglobulins, glutathione-S-transferase (GST), hemagglutinin (HA), and truncated myc.

### 3. Antibodies

KLK-L Related Proteins of the invention can be used to prepare antibodies specific for the proteins. Antibodies can be prepared which bind a distinct epitope in an unconserved region of the protein. An unconserved region of the protein is one that does not have substantial  
25 sequence homology to other proteins. A region from a conserved region such as a well-characterized domain can also be used to prepare an antibody to a conserved region of a KLK-L Related Protein. Antibodies having specificity for a KLK-L Related Protein may also be raised from fusion proteins created by expressing fusion proteins in bacteria as described herein.

30 The invention can employ intact monoclonal or polyclonal antibodies, and immunologically active fragments (e.g. a Fab, (Fab)<sub>2</sub> fragment, or Fab expression library fragments and epitope-binding fragments thereof), an antibody heavy chain, and antibody light

chain, a genetically engineered single chain Fv molecule (Ladner et al, U.S. Pat. No. 4,946,778), or a chimeric antibody, for example, an antibody which contains the binding specificity of a murine antibody, but in which the remaining portions are of human origin. Antibodies including monoclonal and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art.

4. Applications of the Nucleic Acid Molecules, KLK-L Related Proteins, and Antibodies of the Invention

The nucleic acid molecules, KLK-L Related Proteins, and antibodies of the invention may be used in the prognostic and diagnostic evaluation of cancer (e.g. breast, testicular, and prostate cancer), and the identification of subjects with a predisposition to cancer (Section 4.1.1 and 4.1.2). Methods for detecting nucleic acid molecules and KLK-L Related Proteins of the invention, can be used to monitor cancer by detecting KLK-L Related Proteins and nucleic acid molecules encoding KLK-L Related Proteins. It would also be apparent to one skilled in the art that the methods described herein may be used to study the developmental expression of KLK-L Related Proteins and, accordingly, will provide further insight into the role of KLK-L Related Proteins. The applications of the present invention also include methods for the identification of compounds that modulate the biological activity of *KLK-L* or KLK-L Related Proteins (Section 4.2). The compounds, antibodies etc. may be used for the treatment of cancer (Section 4.3).

4.1 Diagnostic Methods

A variety of methods can be employed for the diagnostic and prognostic evaluation of cancer (e.g. breast, testicular, and prostate cancer), and the identification of subjects with a predisposition to cancer. Such methods may, for example, utilize nucleic acid molecules of the invention, and fragments thereof, and antibodies directed against KLK-L Related Proteins, including peptide fragments. In particular, the nucleic acids and antibodies may be used, for example, for: (1) the detection of the presence of *KLK-L* mutations, or the detection of either over- or under-expression of *KLK-L* mRNA relative to a non-disorder state or the qualitative or quantitative detection of alternatively spliced forms of *KLK-L* transcripts which may correlate with certain conditions or susceptibility toward such conditions; and (2) the detection of either an over- or an under-abundance of KLK-L Related Proteins relative to a non-disorder state or the presence of a modified (e.g., less than full-length) KLK-L Protein which correlates

with a disorder state, or a progression toward a disorder state.

The methods described herein may be performed by utilizing pre-packaged diagnostic kits comprising at least one specific *KLK-L* nucleic acid or antibody described herein, which may be conveniently used, e.g., in clinical settings, to screen and diagnose patients and to screen and identify those individuals exhibiting a predisposition to developing a disorder.

Nucleic acid-based detection techniques are described, below, in Section 4.1.1. Peptide detection techniques are described, below, in Section 4.1.2. The samples that may be analyzed using the methods of the invention include those which are known or suspected to express *KLK-L* or contain *KLK-L* Related Proteins. The samples may be derived from a patient or a cell culture, and include but are not limited to biological fluids, tissue extracts, freshly harvested cells, and lysates of cells which have been incubated in cell cultures.

#### **4.1.1 Methods for Detecting Nucleic Acid Molecules of the Invention**

The nucleic acid molecules of the invention allow those skilled in the art to construct nucleotide probes for use in the detection of nucleic acid sequences of the invention in samples. Suitable probes include nucleic acid molecules based on nucleic acid sequences encoding at least 5 sequential amino acids from regions of the *KLK-L* Protein, preferably they comprise 15 to 30 nucleotides. A nucleotide probe may be labeled with a detectable substance such as a radioactive label which provides for an adequate signal and has sufficient half-life such as  $^{32}\text{P}$ ,  $^3\text{H}$ ,  $^{14}\text{C}$  or the like. Other detectable substances which may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a labeled antigen, and luminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. Labeled probes may be hybridized to nucleic acids on solid supports such as nitrocellulose filters or nylon membranes as generally described in Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual (2nd ed.). The nucleic acid probes may be used to detect genes, preferably in human cells, that encode *KLK-L* Related Proteins. The nucleotide probes may also be useful in the diagnosis of cancer; in monitoring the progression of cancer; or monitoring a therapeutic treatment.

The probe may be used in hybridization techniques to detect genes that encode *KLK-L* Related Proteins. The technique generally involves contacting and incubating nucleic acids (e.g. recombinant DNA molecules, cloned genes) obtained from a sample from a patient or other

cellular source with a probe of the present invention under conditions favorable for the specific annealing of the probes to complementary sequences in the nucleic acids. After incubation, the non-annealed nucleic acids are removed, and the presence of nucleic acids that have hybridized to the probe if any are detected.

- 5           The detection of nucleic acid molecules of the invention may involve the amplification of specific gene sequences using an amplification method such as PCR, followed by the analysis of the amplified molecules using techniques known to those skilled in the art. Suitable primers can be routinely designed by one of skill in the art.

- 10           Genomic DNA may be used in hybridization or amplification assays of biological samples to detect abnormalities involving *klk-1* structure, including point mutations, insertions, deletions, and chromosomal rearrangements. For example, direct sequencing, single stranded conformational polymorphism analyses, heteroduplex analysis, denaturing gradient gel electrophoresis, chemical mismatch cleavage, and oligonucleotide hybridization may be utilized.

- 15           Genotyping techniques known to one skilled in the art can be used to type polymorphisms that are in close proximity to the mutations in a *klk-1* gene. The polymorphisms may be used to identify individuals in families that are likely to carry mutations. If a polymorphism exhibits linkage disequilibrium with mutations in a *klk-1* gene, it can also be used to screen for individuals in the general population likely to carry mutations. Polymorphisms which may be used include restriction fragment length polymorphisms (RFLPs), single-base polymorphisms, and simple sequence repeat polymorphisms (SSLPs).
- 20

A probe of the invention may be used to directly identify RFLPs. A probe or primer of the invention can additionally be used to isolate genomic clones such as YACs, BACs, PACs, cosmids, phage or plasmids. The DNA in the clones can be screened for SSLPs using hybridization or sequencing procedures.

- 25           Hybridization and amplification techniques described herein may be used to assay qualitative and quantitative aspects of *klk-1* expression. For example, RNA may be isolated from a cell type or tissue known to express *klk-1* and tested utilizing the hybridization (e.g. standard Northern analyses) or PCR techniques referred to herein. The techniques may be used to detect differences in transcript size which may be due to normal or abnormal alternative splicing. The techniques may be used to detect quantitative differences between levels of full length and/or alternatively splice transcripts detected in normal individuals relative to those individuals
- 30



exhibiting cancer symptoms or other disease conditions.

The primers and probes may be used in the above described methods *in situ* i.e directly on tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections.

#### 4.1.2 Methods for Detecting KLK-L Related Proteins

5        Antibodies specifically reactive with a KLK-L Related Protein, or derivatives, such as enzyme conjugates or labeled derivatives, may be used to detect KLK-L Related Proteins in various samples (e.g. biological materials). They may be used as diagnostic or prognostic reagents and they may be used to detect abnormalities in the level of KLK-L Related Proteins expression, or abnormalities in the structure, and/or temporal, tissue, cellular, or subcellular  
10       location of a KLK-L Related Protein. Antibodies may also be used to screen potentially therapeutic compounds *in vitro* to determine their effects on cancer, and other conditions. *In vitro* immunoassays may also be used to assess or monitor the efficacy of particular therapies. The antibodies of the invention may also be used *in vitro* to determine the level of KLK-L expression in cells genetically engineered to produce a KLK-L Related Protein.

15       The antibodies may be used in any known immunoassays which rely on the binding interaction between an antigenic determinant of a KLK-L Related Protein and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex agglutination, hemagglutination, and histochemical tests. The antibodies may be used to detect and quantify KLK-L Related Proteins  
20       in a sample in order to determine its role in particular cellular events or pathological states, and to diagnose and treat such pathological states.

      In particular, the antibodies of the invention may be used in immuno-histochemical analyses, for example, at the cellular and sub-subcellular level, to detect a KLK-L Related Protein, to localize it to particular cells and tissues, and to specific subcellular locations, and to  
25       quantitate the level of expression.

      Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect a KLK-L Related Protein. Generally, an antibody of the invention may be labeled with a detectable substance and a KLK-L Related Protein may be localised in tissues and cells based upon the presence of the detectable substance. Examples  
30       of detectable substances include, but are not limited to, the following: radioisotopes (e.g.,  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{35}\text{S}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), luminescent

labels such as luminol; enzymatic labels (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase, acetylcholinesterase), biotinyl groups (which can be detected by marked avidin e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or calorimetric methods), predetermined polypeptide epitopes  
5 recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached via spacer arms of various lengths to reduce potential steric hindrance. Antibodies may also be coupled to electron dense substances, such as ferritin or colloidal gold, which are readily visualised by electron microscopy.

10 The antibody or sample may be immobilized on a carrier or solid support which is capable of immobilizing cells, antibodies etc. For example, the carrier or support may be nitrocellulose, or glass, polyacrylamides, gabbros, and magnetite. The support material may have any possible configuration including spherical (e.g. bead), cylindrical (e.g. inside surface of a test tube or well, or the external surface of a rod), or flat (e.g. sheet, test strip). Indirect  
15 methods may also be employed in which the primary antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against KLK-L Related Protein. By way of example, if the antibody having specificity against a KLK-L Related Protein is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labeled with a detectable substance as described herein.

20 Where a radioactive label is used as a detectable substance, a KLK-L Related Protein may be localized by radioautography. The results of radioautography may be quantitated by determining the density of particles in the radioautographs by various optical methods, or by counting the grains.

#### 4.2 Methods for Identifying or Evaluating Substances/Compounds

25 The methods described herein are designed to identify substances that modulate the biological activity of a KLK-L Related Protein including substances that bind to KLK-L Related Proteins, or bind to other proteins that interact with a KLK-L Related Protein, to compounds that interfere with, or enhance the interaction of a KLK-L Related Protein and substances that bind to the KLK-L Related Protein or other proteins that interact with a KLK-L  
30 Related Protein. Methods are also utilized that identify compounds that bind to KLK-L regulatory sequences.

The substances and compounds identified using the methods of the invention include but are not limited to peptides such as soluble peptides including Ig-tailed fusion peptides, members of random peptide libraries and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids, phosphopeptides (including members of  
5 random or partially degenerate, directed phosphopeptide libraries), antibodies [e.g. polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, single chain antibodies, fragments, (e.g. Fab, F(ab)<sub>2</sub>, and Fab expression library fragments, and epitope-binding fragments thereof)], and small organic or inorganic molecules. The substance or compound may be an endogenous physiological compound or it may be a natural or synthetic compound.

10 Substances which modulate a KLK-L Related Protein can be identified based on their ability to bind to a KLK-L Related Protein. Therefore, the invention also provides methods for identifying substances which bind to a KLK-L Related Protein. Substances identified using the methods of the invention may be isolated, cloned and sequenced using conventional techniques.

Substances which can bind with a KLK-L Related Protein may be identified by reacting  
15 a KLK-L Related Protein with a test substance which potentially binds to a KLK-L Related Protein, under conditions which permit the formation of substance-KLK-L Related Protein complexes and removing and/or detecting the complexes. The complexes can be detected by assaying for substance-KLK-L Related Protein complexes, for free substance, or for non-complexed KLK-L Related Protein. Conditions which permit the formation of substance-KLK-  
20 L Related Protein complexes may be selected having regard to factors such as the nature and amounts of the substance and the protein.

The substance-protein complex, free substance or non-complexed proteins may be isolated by conventional isolation techniques, for example, salting out, chromatography, electrophoresis, gel filtration, fractionation, absorption, polyacrylamide gel electrophoresis,  
25 agglutination, or combinations thereof. To facilitate the assay of the components, antibody against KLK-L Related Protein or the substance, or labeled KLK-L Related Protein, or a labeled substance may be utilized. The antibodies, proteins, or substances may be labeled with a detectable substance as described above.

A KLK-L Related Protein, or the substance used in the method of the invention may be  
30 insolubilized. For example, a KLK-L Related Protein, or substance may be bound to a suitable carrier such as agarose, cellulose, dextran, Sephadex, Sepharose, carboxymethyl cellulose

polystyrene, filter paper, ion-exchange resin, plastic film, plastic tube, glass beads, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The carrier may be in the shape of, for example, a tube, test plate, beads, disc, sphere etc. The insolubilized protein or substance may be prepared by reacting the material with a suitable insoluble carrier using known chemical or physical methods, for example, cyanogen bromide coupling.

The invention also contemplates a method for evaluating a compound for its ability to modulate the biological activity of a KLK-L Related Protein of the invention, by assaying for an agonist or antagonist (i.e. enhancer or inhibitor) of the binding of a KLK-L Related Protein with a substance which binds with a KLK-L Related Protein. The basic method for evaluating if a compound is an agonist or antagonist of the binding of a KLK-L Related Protein and a substance that binds to the protein, is to prepare a reaction mixture containing the KLK-L Related Protein and the substance under conditions which permit the formation of substance-KLK-L Related Protein complexes, in the presence of a test compound. The test compound may be initially added to the mixture, or may be added subsequent to the addition of the KLK-L Related Protein and substance. Control reaction mixtures without the test compound or with a placebo are also prepared. The formation of complexes is detected and the formation of complexes in the control reaction but not in the reaction mixture indicates that the test compound interferes with the interaction of the KLK-L Related Protein and substance. The reactions may be carried out in the liquid phase or the KLK-L Related Protein, substance, or test compound may be immobilized as described herein. The ability of a compound to modulate the biological activity of a KLK-L Related Protein of the invention may be tested by determining the biological effects on cells.

It will be understood that the agonists and antagonists i.e. inhibitors and enhancers that can be assayed using the methods of the invention may act on one or more of the binding sites on the protein or substance including agonist binding sites, competitive antagonist binding sites, non-competitive antagonist binding sites or allosteric sites.

The invention also makes it possible to screen for antagonists that inhibit the effects of an agonist of the interaction of KLK-L Related Protein with a substance which is capable of binding to the KLK-L Related Protein. Thus, the invention may be used to assay for a compound that competes for the same binding-site of a KLK-L Related Protein.

The invention also contemplates methods for identifying compounds that bind to proteins that interact with a KLK-L Related Protein. Protein-protein interactions may be identified using conventional methods such as co-immunoprecipitation, crosslinking and co-purification through gradients or chromatographic columns. Methods may also be employed that  
5 result in the simultaneous identification of genes which encode proteins interacting with a KLK-L Related Protein. These methods include probing expression libraries with labeled KLK-L Related Protein.

Two-hybrid systems may also be used to detect protein interactions *in vivo*. Generally, plasmids are constructed that encode two hybrid proteins. A first hybrid protein consists of the  
10 DNA-binding domain of a transcription activator protein fused to a KLK-L Related Protein, and the second hybrid protein consists of the transcription activator protein's activator domain fused to an unknown protein encoded by a cDNA which has been recombined into the plasmid as part of a cDNA library. The plasmids are transformed into a strain of yeast (e.g. *S. cerevisiae*) that contains a reporter gene (e.g. lacZ, luciferase, alkaline phosphatase, horseradish peroxidase)  
15 whose regulatory region contains the transcription activator's binding site. The hybrid proteins alone cannot activate the transcription of the reporter gene. However, interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product.

It will be appreciated that fusion proteins may be used in the above-described methods.  
20 In particular, KLK-L Related Proteins fused to a glutathione-S-transferase may be used in the methods.

The reagents suitable for applying the methods of the invention to evaluate compounds that modulate a KLK-L Related Protein may be packaged into convenient kits providing the necessary materials packaged into suitable containers. The kits may also include suitable  
25 supports useful in performing the methods of the invention.

#### 4.3 Compositions and Treatments

The substances or compounds identified by the methods described herein, antibodies, and antisense nucleic acid molecules of the invention, and peptides may be used for modulating the biological activity of a KLK-L Related Protein, and they may be used in the treatment of  
30 conditions such as cancer (e.g. prostate, testicular, or breast cancer). Accordingly, the substances, antibodies, peptides, and compounds may be formulated into pharmaceutical

compositions for administration to subjects in a biologically compatible form suitable for administration *in vivo*. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the active substance to be administered in which any toxic effects are outweighed by the therapeutic effects. The active substances may be administered to living organisms including humans, and animals. Administration of a therapeutically active amount of a pharmaceutical composition of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of antibody to elicit a desired response in the individual. Dosage regima may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the substance from the action of enzymes, acids and other natural conditions that may inactivate the substance.

The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the active substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

Based upon their homology to genes encoding kallikrein, nucleic acid molecules of the invention may be also useful in the treatment of conditions such as hypertension, cardiac hypertrophy, arthritis, inflammatory disorders, and blot clotting disorders.

Vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used to deliver nucleic acid molecules to a targeted organ,

60427386 640169

tissue or cell population. Methods well known to those skilled in the art may be used to construct recombinant vectors which will express antisense nucleic acid molecules of the invention. (See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra)).

5       The nucleic acid molecules comprising full length cDNA sequences and/or their regulatory elements enable a skilled artisan to use sequences encoding a protein of the invention as an investigative tool in sense (Yousoufian H and H F Lodish 1993 Mol Cell Biol 13:98-104) or antisense (Eguchi et al (1991) Annu Rev Biochem 60:631-652) regulation of gene function. Such technology is well known in the art, and sense or antisense oligomers, or larger fragments,  
10       can be designed from various locations along the coding or control regions.

Genes encoding a protein of the invention can be turned off by transfecting a cell or tissue with vectors which express high levels of a desired KLK-L-encoding fragment. Such constructs can inundate cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules  
15       until all copies are disabled by endogenous nucleases.

Modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the regulatory regions of a gene encoding a protein of the invention, ie, the promoters, enhancers, and introns. Preferably, oligonucleotides are derived from the transcription initiation site, eg, between -10 and +10 regions of the leader sequence. The  
20       antisense molecules may also be designed so that they block translation of mRNA by preventing the transcript from binding to ribosomes. Inhibition may also be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Therapeutic advances using triplex DNA were reviewed by Gee J E et al (In: Huber B E and B  
25       I Carr (1994) Molecular and Immunologic Approaches, Futura Publishing Co, Mt Kisco N.Y.).

Ribozymes are enzymatic RNA molecules that catalyze the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. The invention therefore contemplates  
30       engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding a protein of the invention.

Specific ribozyme cleavage sites within any potential RNA target may initially be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once the sites are identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be determined by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Methods for introducing vectors into cells or tissues include those methods discussed herein and which are suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors may be introduced into stem cells obtained from a patient and clonally propagated for autologous transplant into the same patient (See U.S. Pat. Nos. 5,399,493 and 5,437,994). Delivery by transfection and by liposome are well known in the art.

The nucleic acid molecules disclosed herein may also be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including but not limited to such properties as the triplet genetic code and specific base pair interactions.

The activity of the substances, compounds, antibodies, nucleic acid molecules, and compositions of the invention may be confirmed in animal experimental model systems.

The following non-limiting example is illustrative of the present invention:

#### Example

#### MATERIALS AND METHODS

##### Identification of positive PAC and BAC genomic clones from a human genomic DNA library

The sequence of PSA, KLK1, KLK2, NES1 and Zyme genes is already known. Polymerase chain reaction (PCR)-based amplification protocols have been developed which allowed generation of PCR products specific for each one of these genes. Using these PCR products as probes, labeled with  $^{32}\text{P}$ , a human genomic DNA PAC library and a human genomic DNA BAC library was screened for the purpose of identifying positive clones of approximately 100-150 Kb long. The general strategies for these experiments have been published elsewhere (14). The genomic libraries were spotted in duplicate on nylon membranes and positive clones



were further confirmed by Southern blot analysis as described (14).

#### **DNA sequences on chromosome 19**

The Lawrence Livermore National Laboratory participates in the sequencing of the human genome project and focuses on sequencing chromosome 19. Large sequencing  
5 information on this chromosome is available at the website of the Lawrence Livermore National Laboratory (<http://www-bio.llnl.gov/genome/genome.html>).

Approximately 300 Kb of genomic sequences were obtained from that website, encompassing a region on chromosome 19q13.3 - 13.4, where the known kallikrein genes are localized. This 300 Kb of sequence is represented by 8 contigs of variable lengths. By using  
10 a number of different computer programs, an almost contiguous sequence of the region was established as shown diagrammatically in Figure 1. Some of the contigs were reversed as shown in Figure 1 in order to reconstruct the area on both strands of DNA.

By using the published sequences of PSA, KLK2, NES1 and Zyme and the computer software BLAST 2, using alignment strategies, the relative positions of these genes on the  
15 contiguous map were identified (Figure 1). These known genes served as hallmarks for further studies. An EcoR1 restriction map of the area is also available at the website of the Lawrence Livermore National Laboratory. Using this restriction map and the computer program WebCutter (<http://www.firstmarket.com/cutter/cut2.html>), a restriction study analysis of the available sequence was performed to further confirm the assignment and relative positions of  
20 these contigs along chromosome 19. The obtained configuration and the relative location of the known genes are presented in Figure 1.

#### **Gene prediction analysis**

For exon prediction analysis of the whole genomic area, a number of different computer programs were used. These programs are listed in Table 1. All these programs were initially  
25 tested using known genomic sequences of the PSA, Zyme, and NES1 genes. The more reliable computer programs, GeneBuilder (gene prediction), GeneBuilder (exon prediction), Grail 2 and GENEID-3 were selected for further use.

#### **Protein homology searching**

Putative exons of the new genes were first translated to the corresponding aminoacid  
30 sequences. BLAST homology searching for the proteins encoded by the exons of the putative new genes were performed using the BLASTP program and the Genbank databases.

## RESULTS

### Relative position of PSA, KLK2, Zyme and NES1 on Chromosome 19

Screening of the human BAC library identified two clones which were positive for the Zyme gene (clones BAC 288H1 and BAC 76F7). These BACs were further analyzed by PCR and primers specific for PSA, NES1, KLK1 and KLK2. These analyses indicated that both  
5 BACs were positive for Zyme, PSA and KLK2 and negative for KLK1 and NES1 genes.

Screening of the human PAC genomic library identified a PAC clone which was positive for NES1 (clone PAC 34B1). Further PCR analysis indicated that this PAC clone was positive for NES1 and KLK1 genes and negative for PSA, KLK2 and Zyme. Combination of  
10 this information with the EcoR1 restriction map of the region allowed establishment of the relative positions of these four genes. PSA is the most centromeric, followed by KLK2, Zyme and NES1. Further alignment of the known sequences of these genes with the 300 Kb contig enabled precise localization of all four genes and determination of the direction of transcription, as shown by the arrows in Figure 1. The KLK1 gene sequence was not identified on any of  
15 these contig and appears to be further telomeric to NES1 (since it is co-localized on the same PAC as NES1).

### Identification of new genes

A set of rules was used to consider the presence of a new gene in the genomic area of interest as follows:

- 20 1. Clusters of at least 3 exons should be found.
2. Only exons with high prediction score ("good" or "excellent" quality, as indicated by the searching programs) were considered for the construction of the putative new genes.
3. Exons predicted were reliable only if they were identified by at least two different exon prediction programs.

25 By using this strategy, eleven putative new genes were identified of which three were found on subsequent homology analysis to be known genes not previously mapped i.e. the human stratum corneum chymotrypsin enzyme (HSCCE), human neuropsin, and trypsin-like serine protease (TLSP). Their relative location is shown in Figure 1. In addition, one other putative new gene (gene UG) was identified which showed no homology at the protein level,  
30 with the kallikrein proteins. The five remaining genes all have variable homologies with known human or animal kallikrein proteins and/or other known serine proteases, (depicted as KLK-L1,

KLK-L2, KLK-L3, KLK-L4 and KLK-L5 in Figure 1).

In Tables 2 to 7, the preliminary exon structure and partial protein sequence for each one of the six newly identified genes is shown. In Table 8, some proteins are presented which appear, on preliminary analysis, to be homologous to the proteins encoded by the putative new genes.

## DISCUSSION

Prediction of protein-coding genes in newly sequenced DNA becomes very important after the establishment of large genome sequencing projects. This problem is complicated due to the exon-intron structure of the eukaryotic genes which interrupts the coding sequence in many unequal parts. In order to predict the protein-coding exons and overall gene structure, a number of computer programs were developed. All these programs are based on the combination of potential functional signals with the global statistical properties of known protein-coding regions (15). However, the most powerful approach for gene structure prediction is to combine information about potential functional signals (splice sites, translation start or stop signal etc.) together with the statistical properties of coding sequences (coding potential) along with information about homologies between the predicted protein and known protein families (16).

In mouse and rat, kallikreins are encoded by large multigene families and these genes tend to cluster in groups with a distance as small as 3.3 – 7.0 Kb (3). A strong conservation of gene order between human chromosome 19q13.1 – q13.4 and 17 loci in a 20-cM proximal part of mouse chromosome 7, including the kallikrein locus, has been documented (17).

In humans, only a few kallikrein genes were identified. In fact, only KLK1, KLK2 and KLK3 (PSA) are considered to represent the human kallikrein gene family (9). The work described herein provides strong evidence that a large number of kallikrein-like genes are clustered within a 300Kb region around chromosome 19q13.2 – q13.4. The three established human kallikreins (KLK1, KLK2, KLK3), Zyme and NES1, as well as the stratum corneum chymotryptic enzyme, neuropsin, and TLSP (trypsin-like serine protease) and another five new genes, KLK-L1 to KLK-L5, may constitute a large gene family. This will bring the total number of kallikrein or kallikrein-like genes in this region of chromosome 19 to thirteen.

The human stratum corneum chymotryptic enzyme (19), neuropsin (20) and trypsin-like serine protease (TLSP) (21) are three previously characterized genes which have many structural

similarities with the kallikreins and other members of the serine protease family. However, they have not been mapped in the past. Their precise mapping in the region of the kallikrein gene family indicates that these three genes, along with the ones that were newly identified, or are already known, constitute a family that likely originated by duplication of an ancestral gene.

5 The relative localization of all these genes is depicted in Figure 1.

Kallikrein genes are a subfamily of serine proteases, traditionally characterized by their ability to liberate lysyl-bradykinin (kallidin) from kininogen (18). More recently, however, a new, structural concept has emerged to describe kallikreins. From accumulated sequence data, it is now clear that the mouse has many genes with high homology to kallikrein coding sequences (19-20). Richard and co-workers have contributed to the concept of a "kallikrein multigene family" to refer to these genes (21-22). This definition is not based much on specific enzymatic function of the gene product, but more on its sequence homology and their close linkage on mouse chromosome 7. In humans, only KLK1 meets the functional definition of a kallikrein. KLK2 has trypsin-like enzymatic activity and KLK3 (PSA) has very weak chymotrypsin-like enzymatic activity. These activities of KLK2 and KLK3 are not known to liberate biologically active peptides from precursors. Based on the newer definition, members of the kallikrein family include, not only the gene for the kallikrein enzyme, but also genes encoding other homologous proteases, including the enzyme that processes the precursors of the nerve growth factor and epidermal growth factor (8). Therefore, it is important to note the clear distinction between the enzyme kallikrein and a kallikrein or a kallikrein-like gene.

In carrying out the study only exons were considered which were predicted with "good" or "excellent" quality and only exons were considered which were predicted by at least two different programs. Moreover, the presence of a putative gene was only considered when at least three exons clustered coordinately in that region. Additional evidence that these new genes are indeed homologous to the known kallikreins and other serine proteases comes from comparison of the intron phases. As published previously (14), trypsinogen, PSA and NES1 have 5 coding exons of which the first has intron phase I (the intron occurs after the first nucleotide of the codon), the second has intron phase II (the intron occurs after the second nucleotide and the codon), the third has intron phase I and the fourth has intron phase 0 (the intron occurs between codons). The fifth exon contains the stop codon. The intron phases of the predicted new kallikrein-like genes follow these rules and are shown in the respective tables.

Further support comes from the identification in the new genes, of the conserved amino acids of the catalytic domain of the serine proteases, as presented in **Tables 2 - 6**.

5 In order to test the accuracy of the computer programs, known genomic areas containing the PSA, Zyme and KLK2 genes were tested. Two of these programs (Grail 2 and GeneBuilder) were able to detect about 95% of the tested known genes (data not shown). Matches with expressed sequence tag sequences (EST) can also be employed for gene structure prediction in the GeneBuilder program and this can significantly improve the power of the program especially at high stringency (e.g. >95% homology).

10 In mouse, ten of the kallikrein genes appear to be pseudogenes (9). One of the new genes (UG) does not show homology with the kallikrein genes. However, it has some proein homology with myelin associated glycoprotein (Table 8). There may still be an association between UG and the kallikrein genes since some mouse kallikreins are related to nerve growth factor, as discussed earlier (8) and Zyme as well as neuropsin and TLSP, were found to be highly expressed in brain tissue and it is claimed that Zyme may be related to Alzheimer's disease (11).  
15

Having illustrated and described the principles of the invention in a preferred embodiment, it should be appreciated to those skilled in the art that the invention can be modified in arrangement and detail without departure from such principles. All modifications coming within the scope of the following claims are claimed.  
20

All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

00127306 040300

**FULL CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION**  
**REFERENCES**

1. Evans BAE, Yun ZX, Close JA, Tregear GW, Kitamura N, Nakanishi S, et al. Structure and chromosomal localization of the human renal kallikrein gene. *Biochemistry* 1988;27:3124-3129.
2. Clements JA. The glandular kallikrein family of enzymes: Tissue-specific and hormonal regulation. *Endocr Rev* 1989;10:393-419.
3. Evans BA, Drinkwater CC, Richards RI. Mouse glandular kallikrein genes: Structure and partial sequence analysis of the kallikrein gene locus. *J Biol Chem* 1987;262:8027-8034.
4. Drinkwater CC, Evans BA, Richards RI. Kallikreins, kinins and growth factor biosynthesis. *Trends Biochem Sci* 1988b;13:169-172.
5. Ashley PL, MacDonald RJ. Tissue-specific expression of kallikrein-related genes in the rat. *Biochemistry* 1985;24:5420-5427.
6. Gerald WL, Chao J, Chao L. Sex dimorphism and hormonal regulation of rat tissue kallikrein mRNA. *Biochim Biophys Acta* 1986;867:16-23.
7. Riegman PHJ, Vlietstra RJ, van der Korput JAGM, Romijn JC, Trapman J. Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene. *Biochem Biophys Res Commun* 1989;159:95-102.
8. Schedlich LJ, Bennetts BH, Morris BJ. Primary structure of a human glandular kallikrein gene. *DNA* 1987;6:429-437.
9. Riegman PH, Vlietstra RJ, Suurmeijer L, Cleutjens CBJM, Trapman J. Characterization of the human kallikrein locus. *Genomics* 1992;14:6-11.
10. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. *Mol Med* 1996;2:624-636.
11. Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. *J Biol Chem* 1997;272:25135-25142.
12. Yamashiro K, Tsuruoka N, Kodama S, Tsujimoto M, Yamamura Y, Tanaka T, et al. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially

- expressed in brain. *Biochim Biophys Acta* 1997;1350:11-14.
13. Liu XL, Wazer DE, Watanabe K, Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. *Cancer Res* 1996;56:3371-3379.
- 5 14. Luo L, Herbrick J-A, Scherer SW, Beatty B, Squire J, Diamandis EP. Structural characterization and mapping of the normal epithelial cell-specific 1 gene. *Biochem Biophys Res Commun* 1998;247:580-586.
15. Milanesi L, Kolchanov N, Rogozin I, Kel A, Titov I. Sequence functional inference. In: "Guide to human genome computing", ed. M.J. Bishop, Academic Press, Cambridge, 1994, 249-312.
- 10 16. Burset M, Guigo R. Evaluation of gene structure prediction programs. *Genomics* 1996;34:353-367.
17. Nadeau J, Grant P, Kosowsky M. Mouse and human homology map. *Mouse Genome* 1991;89:31-36.
- 15 18. Schachter M. Kallikreins (kininogenases) - a group of serine proteases with bioregulatory actions. *Pharmacol Rev* 1980;31:1-17.
19. Morris BJ, Catanzaro DF, Richards RI, Mason AJ, Shine J. Kallikrein and renin: Molecular biology and biosynthesis. *Clin Sci* 1981;61:351s-353s.
20. Richards RI, Catanzaro DF, Mason AJ, Morris BJ, Baxter JD, Shine J. Mouse glandular kallikrein genes. Nucleotide sequence of cloned cDNA coding for a member of the kallikrein arginyl estero-peptidase group of serine proteases. *J Biol Chem* 1982;257:2758-2761.
- 20 21. Van Leeuwen BH, Evans BA, Tregear GW, Richards RI. Mouse glandular kallikrein genes. Identification, structure and expression of the renal kallikrein gene. *J Biol Chem* 1986; 261:5529-5535.
- 25 22. Evans BA, Richards RI. Genes for the  $\alpha$  and  $\gamma$  subunits of mouse nerve growth factor. *EMBO J* 1985; 4:133-138.
23. Rogozin IB, Milanesi L, Kolchanov NA. Gene structure prediction using information on homologous protein sequence. *Comput Applic Biosci* 1996;12:161-170.

Table 1. Exon or gene prediction programs used in this study.

No.	Program name	Source	Website or e-mail address
1	GeneBuilder (gene prediction)	Institute of Advanced Biomedical Technologies	<a href="http://l25.itba.mi.cnr.it/~webgene/genebuilder.html">http://l25.itba.mi.cnr.it/~webgene/genebuilder.html</a>
2	GeneBuilder(exon prediction)	Institute of Advanced Biomedical Technologies	<a href="http://l25.itba.mi.cnr.it/~webgene/genebuilder.html">http://l25.itba.mi.cnr.it/~webgene/genebuilder.html</a>
3	ORF gene	Institute of Advanced Biomedical Technologies	<a href="http://l25.itba.mi.cnr.it/~webgene/wwworfgene2.html">http://l25.itba.mi.cnr.it/~webgene/wwworfgene2.html</a>
4	GENEID-3	BioMolecular Engineering Research Center, Boston University	<a href="http://apollo.imim.es/geneid.html">http://apollo.imim.es/geneid.html</a> ( <a href="mailto:geneid@darwin.bu.edu">geneid@darwin.bu.edu</a> )
5	Grail 2	Oak Ridge National Laboratory	<a href="http://compbio.ornl.gov">http://compbio.ornl.gov</a>
6	FGENEH	Baylor College of Medicine, Houston, Texas	<a href="http://mcrb.bcm.tmc.edu">http://mcrb.bcm.tmc.edu</a>

1. In the final analysis of the sequences programs 1, 2, 4 and 5 only were used.



Table 2. Predicted exons of the putative gene KLK-L1. The translated protein sequences of each exon (open reading frame) are shown.

Exon No. <sup>1</sup>	Putative coding region <sup>2</sup>	No. of bases	Translated protein sequence	EST match <sup>3</sup>	Intron phase <sup>4</sup>	Stop codon <sup>5</sup>	Catalytic triad <sup>6</sup>	Exon prediction program <sup>7</sup>
2	From(bp) 2263 To (bp) 2425	163	SLVSGSCQINGEDCSHPQWQAALVMENELFCGV LVHPQWVLSAAHCFQ	+	II	-	H	A,B,D
3	2847 3109	263	NSYTIQLHSLSEADQEPQSMVEASLSVRHPEYNRPL LANDLMLIKLDESVSSEDTIRISIASQCPTAGNSCLVSG WLLANGELT	+	I	-	D	A,B,C,D
4	3180 3317	137	GRMPTVLQCVNVSVVSEVCSKLYDPLYPHSMFCAGG GQDQKDSN	+	0	-		A,B,C,D
5	4588 4737	150	GDSGGPLICNGYLQGLVSGKAPCGQGVGVVYNLC KFTIEWIEKTVQAS	+	-	+	S	A,B,C

1. Conventional numbering of exons in comparison to the five coding exons of PSA, as described in Ref.14.

2. Nucleotide numbers refer to the related contig (see text and figure 1).

3. (+) = >95% homology with published human EST sequences.

4. Intron phase: 0 = the intron occurs between codons; I = the intron occurs after the first nucleotide of the codon; II = the intron occurs after the second nucleotide of the codon.

5. (+) denotes the exon containing the stop codon.

6. H = histidine, D = aspartic acid, S = serine. The aminoacids of the catalytic triad are bold and underlined.

7. A = GeneBuilder (gene analysis), B = GeneBuilder (exon analysis), C = Grail 2,

D = GENEID-3

Table 3. Predicted exons of the putative gene KLK-L2. The translated protein sequences of each exon (open reading frame) are shown.

Exon No.	Putative coding sequence From(bp) To(bp)	No. of bases	Translated protein sequence	EST match	Intron phase	Stop codon	Catalytic triad	Exon prediction program
1	15,361 15,433	73	MATARPPWMMVLCALITALLGVT	+	I	-	-	-
2	17,904 18,165	262	EHVLANNVSCDHPSTNTVPSGSDNODLGAGAGEDARSDSSRIIN GSDCDMHTQPWQAALLLRPNQILYCGAVLVHRQWLLTAAHCRK K	+	II	-	H	A,B,C,D
3	18,903 19,159	257	VFRVRLGHYSLSPVYESGQOMFOGVKSIHPGYSHPGHSNDLMLI KLNRRIRPTKDVRIINVSSEHCFSAGTKCLVSGWGTTSPO	+	I	-	D	C,D
4	19,245 19,378	134	VHFPKVLQELNLSVLSQKRCEDAVPRODDTMFCAGDKAGRDS Q	+	0	-	-	B,C
5	24,232 24,384	153	QDSGQPVVNCVSLQGLVSVGDYPCARPNRPGVVTNLCKFTKI QETIQANS	+	-	+	S	A,B,C

\* All footnotes same as table 2.

Table 4. Predicted exons of the putative gene KLK-L3. The translated protein sequences of each exon (open reading frame) are shown

Exon No. <sup>1</sup>	Putative coding region <sup>2</sup> From(bp) To(bp)	No. of bases	Translated protein sequence	EST match <sup>3</sup>	Intron phase <sup>4</sup>	Stop codon <sup>5</sup>	Catalytic triad <sup>6</sup>	Exon prediction program <sup>7</sup>
1	70,473 70,584	112	VHPTPINHRGGPMEEEGDMAYHKEALDAGCTFQDP	-	I	-	-	A,B,C,D
2	70,764 70,962	199	ACSSLTPLSLIPTFGHGWDTRAIGAEBCRPNSQFWQAGLF HLTRLFCGATLISDRWLLTAHCRK	+	II	-	H	A,B,C,D
3	73,395 73,687	293	PLTSEACPSRYLVVRLGEHHLWKWEGPEQLFRVTDFFPH GFNKDLSANDHNDIMLRLPRQARLSPAVQPLNLSQTCV SPGMQCLISGWGAVSSPK	+	I	-	D	A,B,C,D
4	76,305 76,441	137	ALFPVTLQCANISILENKCHWAYYPGHISDSMLCAGLWEG GRGSCQ	+	0	-	-	A,B,C,D
5	76,884 77,633	749	GDGGGLVLCNGTLGQVYSGGAEPSCRPRPFAVYTSVCHYL DWIQEIMEN	-	-	+	S	A,B

\* All footnotes same as table 2.

Table 5. Predicted exons of the putative gene KLK-1.4. The translated protein sequences of each exon (open reading frame) are shown.

Exon No.	Putative coding region <sup>a</sup> From(bp) To(bp)	No. of bases	Translated protein sequence	EST match <sup>a</sup>	Intron phase <sup>a</sup>	Stop codon <sup>a</sup>	Catalytic triad <sup>a</sup>	Exon prediction program <sup>a</sup>
2	24,945 25,120	176	ESSKVLNTNGTSGFLPGGYTCFPHSQPWQAALLVQGRLL CGVLYHPKWWVIAHCLKE	+	II	-	H	C
3	25,460 25,728	269	GLKVVLGKHALGRVEAGEQREVVHSIPHEYSPTHL NHDHIMLLLEIQSPVQETGMQTLPLSHNNRLTPGTTTCRV SGWGTTSPO	+	I	-	D	A,B,C,D
4	26,879 27,015	137	VNYPKTLQCANIQLRSDDECRQVVPKIDNNMLCAGTKE GKDSCE	+	0	-	-	A,B,C,D
5	28,778 28,963	189	GDSGGLVCNRTLTVGVSWGDFPGQDPDPGVVTRVSRV VLWIRETRKVEYEQQKWLKGRQ	+	+	+	S	A,B,C

<sup>a</sup> All footnotes same as table 2.

Table 6. Predicted exons of the putative gene KLIK-L5. The translated protein sequences of each exon (open reading frame) are shown

Exon No. <sup>1</sup>	Putative coding region <sup>2</sup> From(bp) To(bp)	No. of bases	Translated protein sequence	EST match <sup>3</sup>	Intron phase <sup>4</sup>	Stop codon <sup>5</sup>	Catalytic triad <sup>6</sup>	Exon prediction program <sup>7</sup>
2	1588 1747	160	LSQAATPKIFNGTECORN SQPWQVQLFEGTSLRCGGV LIDHRWVL TAAHCSG	-	II	-	H	A,B,C
3	3592 3851	260	SRYVVRVLGEHSLQLDWTEQIRHSQFSVTHPGYLGAS TSHEHDLRLRLRPVRTSSVQPLPLPNDCATAGTEC HVSQWGITNHR	+	I	-	D	A,B,C,D
4	4806 4939	134	NPFDDLQCLNLSIVSHATCHGVYPGRITSNMVCAGG VPGQDACQ	+	0	-	-	A,B,C,D

\* All footnotes same as table 2.

Table 7. Predicted exons of the unknown gene UG. The translated protein sequences of each exon (open reading frame) are shown.

Exon No.	Putative coding region From(bp) To(bp)	No. of bases	Translated protein sequence	EST match <sup>2</sup>	Intron phase <sup>3</sup>	Stop codon <sup>4</sup>	Exon prediction program <sup>5</sup>
1	44,129 44,641	513	PPLSLEPAVPERITLRNRRSLAALPTDMLLLPLL WGRERAEOQTSKLLTMQSSVTVQEGLEVHVPCSFYPS HGWIYPCPVVHGVWFREGANTDQDAPVATNNPARAV WEETRDHFHLLGDPHTKNCTLSIRDARRSDAGRYFFRM EKGSIKWNYKHHRLSYNVT	+	I	-	B,C
2	44,843 45,121	279	ALTHRNILIPOTLESQCPQNLTCSPWACEQGTTPMIS WIGTSVPLDPSTTRSSVLTUFPQDHTSITCQVTFPG ASVTINKTVHENVSA	+	I	-	A,B,C,D
3	45,327 45,374	48	YPPQNLTMVFQDGI	-	I	-	A,B,D
4	46,318 46,542	225	EGQSLRLVCAYDAVDSNPPARLSLSWRGLTLCPSQPSN PGVLELPWVHEDAAEFTCRQNPQSGQQVYLVNLSLQ	+	I	-	A,B,C
5	47,195 47,283	186	SKATSGVFGGVVGGAGATAPVFLSFGVFN	+	0	-	A,B,C,D
6	49,136 49,554	186	GPLTEPWAEDSPDQPPASARSVGBELQYASLSFQ MVKRWDSRGQEA TDENSEIKHR	+	-	+	A,B,C

\* All footnotes same as table 2.

Table 8 . Homology between the predicted amino acid sequences of the newly identified putative genes and protein sequences deposited in Genbank

No.	Gene identity	Homologous known protein	Identity% (number of amino acids)
1	KLK-L1	<ul style="list-style-type: none"> <li>Human stratum corneum chymotryptic enzyme</li> <li>Rat kallikrein</li> <li>Mouse glandular kallikrein K22</li> <li>Human glandular kallikrein</li> <li>Human prostatic specific antigen</li> <li>Human protease M</li> </ul>	44(101/227) 40( 96/237) 39( 94/236) 38( 93/241) 37( 91/241) 37( 87/229)
2	KLK-L2	<ul style="list-style-type: none"> <li>Human neuropsin</li> <li>Human stratum corneum chymotryptic enzyme</li> <li>Human protease M</li> <li>Human trypsinogen I</li> <li>Rat trypsinogen</li> </ul>	48(106/219) 47(103/216) 45( 99/219) 45(100/221) 44( 98/220)
3	KLK-L3	<ul style="list-style-type: none"> <li>Human neuropsin</li> <li>Rat trypsinogen 4</li> <li>Human protease M</li> <li>Human glandular kallikrein</li> <li>Human prostatic specific antigen</li> </ul>	44(109/244) 39( 95/241) 38( 98/253) 37( 94/248) 36( 89/242)
4	KLK-L4	<ul style="list-style-type: none"> <li>Human protease M</li> <li>Human neuropsin</li> <li>Mouse neuropsin</li> <li>Human glandular kallikrein</li> <li>Human prostatic specific antigen</li> </ul>	52(118/225) 51(116/225) 51(116/226) 48(113/234) 47(108/227)
5	KLK-L5	<ul style="list-style-type: none"> <li>Human neuropsin</li> <li>Rat trypsinogen I</li> <li>Rat trypsinogen II</li> <li>Human protease M</li> </ul>	44( 81/184) 42( 76/178) 42( 75/178) 41( 73/178)
6	UG	<ul style="list-style-type: none"> <li>Human myeloid cell surface antigen CD33</li> <li>Human OB binding protein-2</li> <li>Human OB binding protein-1</li> <li>Human myelin associated glycoprotein</li> </ul>	61(144/233) 50(166/328) 43(189/431) 27( 86/311)

07  
02  
14  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100

**We Claim:**

I. An isolated nucleic acid molecule which comprises:

- (i) a nucleic acid sequence encoding a protein having substantial sequence identity preferably at least 60% sequence identity, with an amino acid sequence of KLK-L1-KLK-L5 as shown in Tables 2 to 6;
- (ii) a nucleic acid sequence encoding a protein comprising with an amino acid sequence of KLK-L1-KLK-L5 as shown in Tables 2 to 6;
- (iii) nucleic acid sequences complementary to (i);
- (iv) a degenerate form of a nucleic acid sequence of (i);
- (v) a nucleic acid sequence capable of hybridizing under stringent conditions to a nucleic acid sequence in (i), (ii) or (iii);
- (vi) a nucleic acid sequence encoding a truncation, an analog, an allelic or species variation of a protein comprising with an amino acid sequence of KLK-L1-KLK-L5 as shown in Tables 2 to 6; or
- (vii) a fragment, or allelic or species variation of (i), (ii) or (iii);



**ABSTRACT OF THE DISCLOSURE**

The invention relates to nucleic acid molecules, proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecules

5

651040-2852100

<b>VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION</b>			Docket No.
Serial No.	Filing Date	Patent No.	Issue Date
Applicant/ Patentee: <b>George M. Yousef, Liu-Ying Luo and Eleftherios P. Diamandis</b>			
Invention: <b>Novel Human Kallikrein-Like Genes</b>			
<p>I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:</p> <p>NAME OF ORGANIZATION: <u>Mount Sinai Hospital</u></p> <p>ADDRESS OF ORGANIZATION: <u>600 University Avenue</u>  <u>Toronto, Ontario</u>  <u>Canada</u>  <u>M5G 1X5</u></p> <p>TYPE OF NONPROFIT ORGANIZATION:</p> <p><input type="checkbox"/> University or other Institute of Higher Education</p> <p><input type="checkbox"/> Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))</p> <p><input type="checkbox"/> Nonprofit Scientific or Educational under Statute of State of The United States of America  Name of State: _____ Citation of Statute: _____</p> <p><input checked="" type="checkbox"/> Would Qualify as Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)) if Located in The United States of America</p> <p><input type="checkbox"/> Would Qualify as Nonprofit Scientific or Educational under Statute of State of The United States of America if Located in The United States of America  Name of State: _____ Citation of Statute: _____</p> <p>I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:</p> <p><input checked="" type="checkbox"/> the specification to be filed herewith.</p> <p><input type="checkbox"/> the application identified above.</p> <p><input type="checkbox"/> the patent identified above.</p> <p>I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above-identified invention.</p> <p>If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).</p>			

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ no such person, concern or organization exists.  
☐ each such person, concern or organization is listed below.

FULL NAME \_\_\_\_\_  
 ADDRESS \_\_\_\_\_

☐ Individual ☒ Small Business Concern ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_  
 ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_  
 ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_  
 ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Terry Donaghue


TITLE IN ORGANIZATION: Director, Technology Transfer & Industrial Liaison

ADDRESS OF PERSON SIGNING: Mount Sinai Hospital  
600 University Avenue  
Toronto, Ontario  
Canada M5G 1X5

SIGNATURE: \_\_\_\_\_

DATE: 3/3/99

**FIGURE 1**



## FIGURE 2

KLK - L 1

TATCTCATGAGAGAGAATAAGAACATGAAAAGAGAAAAGAATGAGAGAGAG  
AGAGAGAAAAGAAAAAGGAGAGTGGAGTCTAGGATCTGGGCAGGGGTCTCC  
TCCCTGGGTCCCTAGACCCTGCTGCCAGCCCCTTCTGGGCCCCCAACCAC  
TGCCTGGTCAGAGTTGAGGCAGCCTGAGAGAGTTGAGCTGGAAGTTTGCA  
GCACCTGACCCCTGGAACACATCCCCTGGGGGCAGGCCAGCCCAGGCTGA  
GGATGCTTATAAGCCCCAAGGAGGCCCTGCGGAGGCAGCAGGCTGGAGC  
TCAGCCCAGCAGTGAATCCAGGAGCCCAGAGGTGGCCGGGTAAAGAGGCC  
TGGTGGTCCCCCACTAAAAGCCTGCAGTGTTCATGATCCAACCTCTCCCTA  
CAGCTCCATGTCGCTGGATTCTCAGCCTCTGTGCCTTCTGTCTCCACATC  
TCTCTAGACAGATCTCTCACTGTCTCTAGTTAGGAGTCACTGTCTCTAGT  
TAGGGGTCTCTGTCTCTCTGAATCTATATCTCCATGTCTAACTCTCAG  
ACTGTCTCTGAGGATATCTCTCAAGCACTCTGTCTCTCCGGCTCTGATTC  
TCTGTGTCTCTCCCTCCATGCTTGTGGGTGGCTAGACACCATCTC  
TCCCCATTACAGATGGCTAGATGCTTTCTCTAAACTTTCTTTCTACCT  
AGTCTCTCTCTCTCTCTTTTCCCCTCTCTCTCTCTTTTCTCTCTCA  
GTCTCTAAATCTGTCTCTCTAGGTTCTGGGTCCATGGATGGGAGAGGGGG  
TAGATGGTCTAGGCTCTTGCCCTACCTAATAACGTCCAGAGGGAAGAAAG  
GGAGGGACAAAGAGAGGGATGGAGAGACTTGGGCTGAAGATCCCCAGACA  
CGGCTAAGTCTCAGTCCTCATCCCCAGGTGCTGACGTGATGGCCACAGCA  
GGAAATCCCTGGGGCTGGTTTCTGGGGTACCTCATCCTTGGTGTGCGAGG  
TATCTGAGTATGCGTGTGTGTGTCTGTCCGTGCTTGGGGGCACAGTGTTC  
GTAAATGTTCAAGGTGTGACTCAGTGTCTCTTGCTTGTGACTGCAAAGCT  
GCCTGTGAGACGGTACCGTGTTATCCGTCCGCCATGGCTGTGCCCTGCA  
ACTCCTTGATCGTGGTAAATTTGTGTGTGGCAGTGTGCCTGGGTGTGTG  
GTTGTACCTGTGAGACTCTGACAGTTTGTGCCTCTGAATATCTGGTGGAG  
TGACAACAGTGTAATGATGATATGGGGACAGGGGAAGCCGAGGGTGCAGG  
AGATTGTGCTTCTGGGGCGTGATCCATTGCTGGGAATCTGTGCCTGCTT  
CCTGGGTCTTCAGTCCTGAGATCCCCCTCTCCCCTCCCCAAGGAACCTCAC  
CTCACAGGACTATAAAACGGTGTTTTGGTGTGCATGGGCTTGTGGCTTGG  
TGTGACTGTGGGCAAGGCTGGGAGAGGATAGGAGTGAAGTCCGGCGCAGGAC  
CGACTCTTTGAGCATCAGTCTGCGCAGACAAGTGACCCGATCCTTGCTCC  
CAGCAACAACCTCCACCCCCTGAGCTTTAATTCACCCCGAAGGACCCGATC  
CTACCGCTATGAGCCTAGACTCCTCTGTTGAACCCCTCCTGACCGTGGCT  
TTGCACCGCGATGGCACCAGTCTCACCTCCAGAGCTCACCCAGAGCCCT  
GACTCCGCCCCAGAAGCCCTGGTCCCACCTTCTGAGACTGCCTCTAGCCA  
TAACCCAGCTCTTGAAGCCTTGATGGCGCCCCTGCGCTGTAACCCCAACC  
CTAGGAGCACTGATCCCGCCTTCTCAGCCCAACCCCATGCCCTGACTCTC

01  
02  
03  
04  
05  
06  
07  
08  
09  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100

## FIGURE 2 (cont'd)

CTCCCAGGAGCCCTGACTACCCTGAATCCCTGACCAGGCTCCTGCACCGT  
 GATCACCGCCCCTGGGAGCCCTAGGCCTATATCCTGGACCAGCCCCTGAA  
 GCTCCGATCATGACCCCTGCACCATAACCCACCCCCAGGAGCCCTGGGT  
 CCGCECCCTGGGCCCCGCCCCAGCCCTGACTCGGCCCCCCAAGAGTCTTG  
 ACTGCTCCTGAAGCCCTGACCACGCCCTGCTCGGTAACCCCTCCCCAA  
 GAGCCCTGGGCCCCGCTCCTGAGCCCCTTCCCAGCCCTGACTCGGCCCG  
 AGGAGCCCTGACTGCTCCTGAACCTCTGACCACGCCCTGCTCGGTAAGC  
 CCACCCCCAGGAACCTGGGCCCGCCTCCTGGTCCCGATCCCATECCTGA  
 CTCCGCCCTCAGGATCTCTCGTCTCTGGTAGCTGCAGCCAAATCATAAAC  
GGCGAGGACTGCAGCCCCGCACTCGCAGCCCTGGCAGGCGGCACTGGTCAT (1)  
GGAAAACGAATTGTTCTGCTCGGGCGTCTGGTGCATCCGCAGTGGGTGC  
TGTCAGCCGCACACTGTTTCCAGAAGTGAQTGCAGAGGTAGGGGGAGTGG  
 GCAGGGCCTGGGTCCGGGGGCGGGGCCCTAATATCAGGCTCATCTTGGGGT  
 GCTCAGGGGGAAACAGCGGTGAAGGCTCTGGGAGGAGGACGGAATGAGCC  
 TGGATCCGGGGAGCCCAGAGGGAAGGGCTGGGAGGCGGGAATCTTGCTTC  
 GGAAGGACTCAGAGAGCCCTGACTTGAAATCTCAGCCCAGTGCTGAGTCT  
 CTAGTGAACATAAGGCAAGTTCTTGTCCTGAATTTTTGTGAATGAGGATT  
 TGAGACCATGGTTAAGTAGCTCTTAGGGTGTGTTAGCGAAGAGGGTGGGGT  
 TGGGGTTAGGAGATGGGGATGGGAATGGGGTTGAAGATGAGAATGGAGGT  
 AAGGATGTAGTTGCCACAAAAGTACCTGCCCTCCGTGGCCACAGCTCC  
TACACCATCGGGCTGGGCCTGCACAGTCTTGAGGCCGACCAAGAGCCAGG (2)  
GAGCCAGATGGTGGAGGCCAGCCTCTCCGTACGGCACCCAGAGTACAACA  
GACCTTGCTCGCTAAGGACCTCATGCTCATGAAGTTGGACGAATCCGTG  
TCCGAGTCTGACACCATCCGGAGCATCAGGATTGCTTCGCAGTGACCTAC  
CGCGGGGAAGTCTTGCCCTCGTTTCTGGGTGGGGTCTGCTGGGGAACGGTG  
AGCTCACGGGTGTGTCTGCCCTCTCAAGGAGGTCTCTGCCAGTCG  
CGGGGGCTGACCCAGAGCTCTGCGTCCAGGCAGAAATGCCTACCGTGCTG  
CAGTGCGTGAACGTGTGCGGTGGTGTCTGAGGAGGTCTGCAGTAAGCTCTA (3)  
TGACCCGCTGTACCACCCAGCATGTTCTGCGCCGGCGGAGGGCAAGACC  
AGAAGGACTCCTGCAACGTGAGAGAGGGGAAAGGGGAGGGCAGGCGACTC  
 AGGGAAGGGTGGAGAAGGGGGAGACAGAGACACACAGGGCCGCATGGCGA  
 GATGCAGAGATGGAGAGACACACAGGGAGACAGTGACAAGTAGAGAGAGA  
 AACTGAGAGAAACAGAGAAATAAACACAGGAATAAAGAGAAGCAAAGGAA  
 GAGAGAAACAGAAACAGACATGGGGAGGCAGAAACACACACACATAGAAA  
 TGCAGTTGACCTTCCAACAGCATGGGGCCTGAGGGCGGTGACCTCCACCC  
 AATAGAAAATCCTCTTATAACTTTTGACTCCCCAAAAACCTGACTAGAAA  
 TAGCCTACTGTTGACGGGGAGCCTTACCAATAACATAAATAGTCGATTTA  
 TGCATACGTTTTATGCATTTCATGATATACCTTTGTTGGAATTTTTTGATA  
 TTTCTAAGCTACACAGTTCGTCTGTGAATTTTTTTAAATTGTTGCAACTC  
 TCCTAAAATTTTTCTGATGTGTTTATTGAAAAAATCCAAGTATAAGTGGA  
 CTTGTGCAGTTCAAACCAAGGGTGTGTTCAAGGGTCACTGTGTATCCAGAG  
 GGAAACAGTGACACAGATTTCATAGAGGTGAAACACGAAGAGAAACAGGAA  
 AAATCAAGACTCTACAAAGAGGCTGGGCAGGGTGGGTCTATGCTGTATC  
 CCAGCACTTTGGGAGGCGAGGCAGGCAGATCACTTGAGGTAAGGAGTTCA  
 AGACCAGCCTGGGCAAAATGGTGAAATCCTGTCTGTAGTAAAAATA'CAAA  
 AGTTAGCTGGATATGGTGGCAGGCGCCTGTAATCCCAGCTACTTGGGAGG

## FIGURE 2 (cont'd)

CTGAGGCAGGAGAATTGCTTGAATATGGGAGGCAGAGGTTGAAGTGAGTT  
GAGATCACACCACTATACTCCAGCTGGGGCAACAGAGTAAGACTCTGTCT  
CAAAAAAAAAAAAAAAAAAGACTTTACAAAGAGATGCAGAGACACTGAGA  
CAGATAACAAGCCACAAAGGAGACAAAGGAGAGACAGACAAACAGAAAC  
AGACAGACCACAAGCCCAAGAGAAGCAGCCAGCATTGAGGACATAGGACA  
TCGGGAAGCAGGATTAGATGAAAGTCAGGGATCTGGAATGGGACTTCCAAC  
AGATATGTTGCTGGGCTATGTTGTTATTGATGATGGTTCTGTCTTTGTTT  
CTCAGTCTCATTAGTTCCTTTCTGAGCCCATATCCATTTCCACCTCTCT  
GTGTTTTGAATTCTGACTCTCCCTCTCTTCACAACAGGGTGAAGTCTGGGG  
GGCCCCTGATCTGCAACGGGTACTTGCAGGGCCTTGTGTCTTTTCGGAAAA (4)  
GCCCCGTGTGGCCAAGTTGGCGTGCCAGGTGTCTACACCAACCTCTGCAA  
ATCACTGAGTGGATAGAGAAAACCGTCCAGGCCAGT7AA STOP

01234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465666768697071727374757677787980818283848586878889909192939495969798991001011021031041051061071081091101111121131141151161171181191201211221231241251261271281291301311321331341351361371381391401411421431441451461471481491501511521531541551561571581591601611621631641651661671681691701711721731741751761771781791801811821831841851861871881891901911921931941951961971981992002012022032042052062072082092102112122132142152162172182192202212222232242252262272282292302312322332342352362372382392402412422432442452462472482492502512522532542552562572582592602612622632642652662672682692702712722732742752762772782792802812822832842852862872882892902912922932942952962972982993003013023033043053063073083093103113123133143153163173183193203213223233243253263273283293303313323333343353363373383393403413423433443453463473483493503513523533543553563573583593603613623633643653663673683693703713723733743753763773783793803813823833843853863873883893903913923933943953963973983994004014024034044054064074084094104114124134144154164174184194204214224234244254264274284294304314324334344354364374384394404414424434444454464474484494504514524534544554564574584594604614624634644654664674684694704714724734744754764774784794804814824834844854864874884894904914924934944954964974984995005015025035045055065075085095105115125135145155165175185195205215225235245255265275285295305315325335345355365375385395405415425435445455465475485495505515525535545555565575585595605615625635645655665675685695705715725735745755765775785795805815825835845855865875885895905915925935945955965975985996006016026036046056066076086096106116126136146156166176186196206216226236246256266276286296306316326336346356366376386396406416426436446456466476486496506516526536546556566576586596606616626636646656666676686696706716726736746756766776786796806816826836846856866876886896906916926936946956966976986997007017027037047057067077087097107117127137147157167177187197207217227237247257267277287297307317327337347357367377387397407417427437447457467477487497507517527537547557567577587597607617627637647657667677687697707717727737747757767777787797807817827837847857867877887897907917927937947957967977987998008018028038048058068078088098108118128138148158168178188198208218228238248258268278288298308318328338348358368378388398408418428438448458468478488498508518528538548558568578588598608618628638648658668678688698708718728738748758768778788798808818828838848858868878888898908918928938948958968978988999009019029039049059069079089099109119129139149159169179189199209219229239249259269279289299309319329339349359369379389399409419429439449459469479489499509519529539549559569579589599609619629639649659669679689699709719729739749759769779789799809819829839849859869879889899909919929939949959969979989991000100110021003100410051006100710081009101010111012101310141015101610171018101910201021102210231024102510261027102810291030103110321033103410351036103710381039104010411042104310441045104610471048104910501051105210531054105510561057105810591060106110621063106410651066106710681069107010711072107310741075107610771078107910801081108210831084108510861087108810891090109110921093109410951096109710981099110011011102110311041105110611071108110911101111111211131114111511161117111811191120112111221123112411251126112711281129113011311132113311341135113611371138113911401141114211431144114511461147114811491150115111521153115411551156115711581159116011611162116311641165116611671168116911701171117211731174117511761177117811791180118111821183118411851186118711881189119011911192119311941195119611971198119912001201120212031204120512061207120812091210121112121213121412151216121712181219122012211222122312241225122612271228122912301231123212331234123512361237123812391240124112421243124412451246124712481249125012511252125312541255125612571258125912601261126212631264126512661267126812691270127112721273127412751276127712781279128012811282128312841285128612871288128912901291129212931294129512961297129812991300130113021303130413051306130713081309131013111312131313141315131613171318131913201321132213231324132513261327132813291330133113321333133413351336133713381339134013411342134313441345134613471348134913501351135213531354135513561357135813591360136113621363136413651366136713681369137013711372137313741375137613771378137913801381138213831384138513861387138813891390139113921393139413951396139713981399140014011402140314041405140614071408140914101411141214131414141514161417141814191420142114221423142414251426142714281429143014311432143314341435143614371438143914401441144214431444144514461447144814491450145114521453145414551456145714581459146014611462146314641465146614671468146914701471147214731474147514761477147814791480148114821483148414851486148714881489149014911492149314941495149614971498149915001501150215031504150515061507150815091510151115121513151415151516151715181519152015211522152315241525152615271528152915301531153215331534153515361537153815391540154115421543154415451546154715481549155015511552155315541555155615571558155915601561156215631564156515661567156815691570157115721573157415751576157715781579158015811582158315841585158615871588158915901591159215931594159515961597159815991600160116021603160416051606160716081609161016111612161316141615161616171618161916201621162216231624162516261627162816291630163116321633163416351636163716381639164016411642164316441645164616471648164916501651165216531654165516561657165816591660166116621663166416651666166716681669167016711672167316741675167616771678167916801681168216831684168516861687168816891690169116921693169416951696169716981699170017011702170317041705170617071708170917101711171217131714171517161717171817191720172117221723172417251726172717281729173017311732173317341735173617371738173917401741174217431744174517461747174817491750175117521753175417551756175717581759176017611762176317641765176617671768176917701771177217731774177517761777177817791780178117821783178417851786178717881789179017911792179317941795179617971798179918001801180218031804180518061807180818091810181118121813181418151816181718181819182018211822182318241825182618271828182918301831183218331834183518361837183818391840184118421843184418451846184718481849185018511852185318541855185618571858185918601861186218631864186518661867186818691870187118721873187418751876187718781879188018811882188318841885188618871888188918901891189218931894189518961897189818991900190119021903190419051906190719081909191019111912191319141915191619171918191919201921192219231924192519261927192819291930193119321933193419351936193719381939194019411942194319441945194619471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047204820492050205120522053205420552056205720582059206020612062206320642065206620672068206920702071207220732074207520762077207820792080208120822083208420852086208720882089209020912092209320942095209620972098209921002101210221032104210521062107210821092110211121122113211421152116211721182119212021212122212321242125212621272128212921302131213221332134213521362137213821392140214121422143214421452146214721482149215021512152215321542155215621572158215921602161216221632164216521662167216821692170217121722173217421752176217721782179218021812182218321842185218621872188218921902191219221932194219521962197219821992200220122022203220422052206220722082209221022112212221322142215221622172218221922202221222222232224222522262227222822292230223122322233223422352236223722382239224022412242224322442245224622472248224922502251225222532254225522562257225822592260226122622263226422652266226722682269227022712272227322742275227622772278227922802281228222832284228522862287228822892290229122922293229422952296229722982299230023012302230323042305230623072308230923102311231223132314231523162317231823192320232123222323232423252326232723282329233023312332233323342335233623372338233923402341234223432344234523462347234823492350235123522353235423552356235723582359236023612362236323642365236623672368236923702371237223732374237523762377237823792380238123822383238423852386238723882389239023912392239323942395239623972398239924002401240224032404240524062407240824092410241124122413241424152416241724182419242024212422242324242425242624272428242924302431243224332434243524362437243824392440244124422443244424452446244724482449245024512452245324542455245624572458245924602461246224632464246524662467246824692470247124722473247424752476247724782479248024812482248324842485248624872488248924902491249224932494249524962497249824992500250125022503250425052506250725082509251025112512251325142515251625172518251925202521252225232524252525262527252825292530253125322533253425352536253725382539254025412542254325442545254625472548254925502551255225532554255525562557255825592560256125622563256425652566256725682569257025712572257325742575257625772578257925802581258225832584258525862587258825892590259125922593259425952596259725982599260026012602260326042605260626072608260926102611261226132614261526162617261826192620262126222623262426252626262726282629263026312632263326342635263626372638263926402641264226432644264526462647264826492650265126522653265426552656265726582659266026612662266326642665266626672668266926702671267226732674267526762677267826792680268126822683268426852686268726882689269026912692269326942695269626972698269927002701270227032704270527062707270827092710271127122713271427152716271727182719272027212722272327242725272627272728272927302731273227332734273527362737273827392740274127422743274427452746274727482749275027512752275327542755275627572758275927602761276227632764276527662767276827692770277127722773277427752776277727782779278027812782278327842785278627872788278927902791279227932794279527962797279827992800280128022803280428052806280728082809281028112812281328142815281628172818281928202821282228232824282528262827282828292830283128322833283428352836283728382839284028412842284328442845284628472848284928502851285228532854285528562857285828592860286128622863286428652866286728682869287028712872287328742875287628772878287928802881288228832884288528862887288828892890289128922893289428952896289728982899290029012902290329042905290629072908290929102911291229132914291529162917291829192920292129222923292429252926292729282929293029312932293329342935293629372938293929402941294229432944294529462947294829492950295129522953295429552956295729582959296029612962296329642965296629672968296929702971297229732974297529762977297829792980298129822983298429852986298729882989299029912992299329942995299629972998299930003001300230033004300530063007300830093010301130123013301430153016301730183019302030213022302330243025302630273028302930303031303230333034303530363037303830393040304130423043304430453046304730483049305030513052305330543055305630573058305930603061306230633064306530663067306830693070307130723073307430753076307730783079308030813082308330843085308630873088308930903091309230933094309530963097309830993100310131023103310431053106310731083109311031113112311331143115311631173118311931203121312231233124312531263127312831293130313131323133313431353136313731383139314031413142314331443145314631473148314931503151315231533154315531563157315831593160316131623163316431653166316731683169317031713172317331743175317631773178317931803181318231833184318531863187318831893190319131923193319431953196319731983199320032013202320332043205320632073208320932103211321232133214321532163217321832193220322132223223322343225322632273228322932303231323232333234323532363237323832393240324132423243324432453246324732483249325032513252325332543255325632573258325932603261326

# FIGURE 3

KLK-L 2

GGGCCCAGAG TGAAGGCAAG AGAAGGAGTT GAGAGCTCCC TCTGCAAAGT GGCTTGAGTC  
TCCCCTGECT AAAATGCAGG GAGAGGGAGG CAGAAAGACA GGGAGAGGA AGGGGTGGGG  
AAGAAAGAGA GAGAGAGAGA GAGACAGAAT AACACAAC TA CAGAAACACA GAGAGAAAG  
ACAGAGAGCC TGGGACACAG GGACACACAG AGTCAGAGAG AAAAGAGAAG ATAGAGAAAG  
ACACAAATGG AGACACAGAG GTGTAAAGAA AGAGAGATTA ACAGAGTCCC AGATAACGC  
AAAGGGGCAG AAGCACAGTT TTCAGGTGG TGTCTATGAT CATCTTCTTT TTTTTTTTTT  
TTTTTTTTTT TTTTGTAGAC GGAGTCTCGC TCTGTGCCCC AGGCTGGAGT GCAGTGGEGG  
GATCTCGGCT CACTGCAAGC TCCGCCTCCC GGGTTCACGC CATTCTCCTG CCTCAGCCTC  
CCAAGTAGCT GGGACTACAG GCGCCCGCCA CTACGCCCCG CTAATTTTTT TGTATTTTTA  
GTAGAGACGG GGTTCACCG TTTTAGCCGG GATGGCCTCG ATCTCCTGAC CTCGTGATCC  
GCCCCCTCG GCCTCCCAA GTGCTGGAT GTACCTAAAG CCATCAGACT CTACCCTTTA  
ATCATCTTCT TGACTATGCT GATGTGACAA GTACCTAAAG ATTCCAGCAC TTGGGAGGC  
AATATGCAGT TTGGGCCAGG CACCGTGGCT CATGCCGTGA TTTGAGACCA GCCTGGCCAA CATGGTGA  
AGAGGTGGGT GAATCACTTG AGGCCAGGAG TTTGAGACCA AGCCGGGTGT CGTGGGGCAC  
CTCTGTCTTT ACTAAAAA AAAAAAATC AGCCGGGTGT CGTGGGGCAC  
ACCTGTAATC CCAGCTATGC TGGAGGCTGA GGCACGAGAG TCACTTGAAC CCTGGAGGCG  
GAGGTTGCAG TGGGCCGAGA TCACATCACC GCCCTCCAGC CTGGGCGACA GAGCAAGACT  
CTGTCTCAA TAAATAAATA AACAAACGAA CAAGCAGTTT GTGTACCTT AGTTATATCT  
AAAAAATAA TGCTGTCAAC AAATAGAGCA GAAGTGAAAT AAAGGAAAT AAATGGGCCA  
AGAACTCTAA GGTATATTG ACAATCATT CAGAACCTTT AAAAAAGAA GAATCACAGA  
GGCATAGAAA GAGAGGGAGG AACAGGGAGA CAGAAACACC TGTGGGEEAA GGAGAACAAA  
ACAAGGCTEC TAAGACAGAG AGGAGGAGAG AGAGAGAGAG TGAGTGAGAG ACAGACAGAG  
AAAAAGACAG AGAGAGAGAG ACAGAGACAG AGAGACAGAG AGGCGAGAGG GATAGAAAGA  
GAGAGAGGGG TGGAGAGAGA CACGAGATAT TGAGAGAGAC TCAGAAAGAT AGCCGAGGGA  
GAACCACAGA GAGATGGAAG AAGACTTGA GAAAAACCA GAGACAAAGA TGGAAAGAGG  
AGTATCGAGG GTGAAGAGAG AGTGGTGGAA TGAGCAAAAT GCAGAGAAGA AAGCAAGCAA  
TCCAGGCCGC AAGAATAGTG ACCCAGAGTT GGTGAGAAGC CAGATCCTTA AGGCTGGGGG  
AGGCAGGGAA GGGGCTGGCC TGGCTTCCGG AGACCECTEC CATTCTCCG GGCCAGGGAG  
GTAGGGAGTG ACATTCCGGA CTGGGTGGGG GGTGTCTGG GGTGGAGAT AGGGGGAGCA  
GGAGGAGCTA TTGCTAAGGC CCGATAGGCA CCTCATTGCC CGGGAATGTG CCGCAGGGAG  
CAGTGGGTGG TTATAAETCA GGCCCGGTGC CCAGAGCCCA GGAGGAGGCA GTGGGAGGA  
AGGCACAGGC CTGAGAAGTC TCGGCTGAG CTGGGAGCAA ATCCCCACC CCCTACCTGG  
GGGACAGGGC AAGTGAGAGC TGGTGAGGGT GGCTCAGCAG GCAGGGAAGG AGAGGTGTET  
GTGCGTCCTG CACCCACATC TTTCTCTGTC CCCTCCTTGC CCTGTCTGGA GGCTGCTAGA  
CTCCTATCTT CTGAATTCTA TAGTGCTTGG GTCTCAGCGC AGTGCCGATG GTGGCCCGTC  
CTTGTGGTTC CTCTCTACCT GGGGAAATAA GGTAGGGGAG GGAGGGGAAG TGGGTTAAGG  
GCTCCCCGGA TCGCCTGGGC CTCCCAACCC TCTGACATTC CCCATCCAGG TGCAGCGGCC  
ATGGCTACAG CAAGACCCCC CTGGATGTGG GTGCTCTGTG CTCTGATCAC AGCCTTGCTT  
CTGGGGGTCA CAGGTAACCA GAACCTCTGG GTGGGAGGGT TGTGGGATTG GGAGGACTGT  
CTCTGCGGCA CTAGAGCGCC TGTCCCCTGG GGAACGTGTG GAGCCTGGGC ATGACTCCGG  
GACCGGGTGA ATGTGAGTCT CTGTCTGTAC TTGTGGTTGT GCGATCGTAT GTGGCCCTGT  
GACTGCCACG GTGTGTGTCG GGGAGGGGGA TGCCCTTTCC CATATCAGGT GACTGTGCGG  
CAGGTGGCAC TGACCCTTTG AGGCTGTGTG TGTGGTTTGT TGATTGTGTG TGCATTTAAG  
ATTGTGTGTG GCTCCACAGC TGTGTGGGTG AATGCATGTA GCACTGGGGG TGTTCAGTGT  
GTGTTTGGCT GTGTGTGGTG ACTTGGCATT GTATATGACT GCAGGTATCT GCAGTTCCTG  
TCCCTGAGGT CCCGGGATTG CGTGCAACAA AAGTGGTCAT CACCATGGAA AGCTGTGACT  
GTGTGCTGCT TGCAGGCGAT TATGTGATTG TGGCTGAGTG TGACGTTATG GATGGGEGTA  
TTTGTGACCG TGTGACTACC TGAAGCTCTG TGTAGGGGTG ACTGTATGTG ACTGTGTGTG  
TCTGTGTGAG GCCGTGTAAA TGCTACTGTA TGTGTGATGG TGCACTGTGT TGTCTGGAGT  
TTCTGTCTCT GCCTGGAGG ATAGAGGGTG CAGGGGTAGC TATCTCTGGG AGATGGGTGG  
CAGGTGAGTG ACTTGEAGTG TGTGCTGTG TGCAGAAAG TATGTGGCAG TCTGAACATC  
TGTGAGACACA CGGCATCTGT GCGTGGGACT GAGAGACTGT GGATGAGGGT GTGCGATCC  
GCTAGGCTGC CCGGAGCGT GTGTACCTGG AGACAGAGCT GTATGTTAGC TGCACCTGTG  
GAGGCAACAT GGGCGTGTCT GCAGAACTGC GTGCGTGCTT GGCTGTACT GCTGTTGTG

7  
6  
5  
4  
3  
2  
1



# FIGURE 3 (cont'd)

GCGTGGTTCT TGGGGTGAGT TCGTGAATGA TGGTGGTGCC AGGGCCATCA GCAAGGGTAA  
 GAACCAGGCC GGGCGCGGTG GCTCACGCCT GTAATCCCAG CCCTTTGGGA GGCCGAGGCA  
 GGCGGATCAC CTGAGGTCGG GAGATCGAGG CCAGCCTGAC CAACATGGAG AACCCCGTCT  
 CTAATAAAAA TACAAAAAAT TAGCTGGTGT GGTGGCGCGT GCCTGTAATC CCAGCTACTC  
 GGGAGACTGG GGCAGAAAAA TCGCTTGAAC CCGGGAGGTG GAGGTTGCGG TGAGCCGAGA  
 TCGCGCCATT GCACTCCAGC CTGGGCAACA AGAGCGAAAC TCCGTCTCGA AAGAAAAAAA  
 GAAAAAATAA AGGGTAAGAA CCAGTGAATG GGCACGGGAG GACTGATGAT GGAGTGGGGC  
 ATGCATGTAG TCTGTAGGTC TGTGTGTGAG AGGAGGAGAT TGACAGGATT GAGAAGGCAT  
 GTTTTCATCT GAGAATTCAG AAACCTAGGC CTGCTCTTCC CCTCCATGTG GCCCCTAAG  
 CTGAGCCCTT CTTTCTGGT CCTGCTTTCG GAACCCTAGC TCCGCCCATG AGCTCTGACC  
 CCACCTCCTT TCCTCAACCA CGCCCCTAGG CCAGACTCTA GTGGACCCCG CCTAAGGCCA  
 CACCCCTTTG GGCCAGGCTC CACCCCTAT TCTGTGGGTA CCTTCTAGAA CCCCCTTCAA  
 AGTCAGAGCT TTTTTTTTTT TTTTTTTGGA GACAGTCTTG CTCTCTCTCC CAGGCTGGAG  
 TGCAGTGGCG TGATCTCGGC TCACTGCAAC CTCTGCCTCC CAGGTTCAAG TGATTTCTCGT  
 GCCTCCACCT CCTGAGTAGC TGGGATTACA GGTGCGCGCC ACCACGCCTG GCTAATTTTTT  
 GTGTCTTTAG TAGAGACAGG GTTTCACCTT GTTGGCCAGG CTGGTCTCAA ACTCCCAACC  
 TCAGGTGATC CGCCACCTC GGCTCCCAG AGTGTGGGG TTACAGGCGT GAGCCACCGC  
 CCCCAGCCCA AAGTCAGAGC TCTTTATAGG AGACTCTAAC ATGTAACCCT GACCCTGGCC  
 CTAACCTAAGT CAATTCCAA CCCCTTCTG CCTCAGCCC TGACCCCACT CACTGAGGCC  
 TGACCCCACT CTTTGAGACC AGTTCCATCC CTAAAGCCCT GGTCTCCCTC CCATCCCCAG  
 GCTCCAGCCC CCACAGCTTT GGCACCTACC CTGAGCTTGT CCAGGAATCC TGTACCCAAT  
 TTTACCCTCA CATGTAGTTC TAGCCAATTC CAGGAATCTG TGAGGTCCAG TTAGAGTCCA  
 GTAACCCTAC CTGAGCCTGG GCTCTGTCTT TGAGCTTGAG CCTGGGCTTG AGAGGTGCCA  
 CTCTTATTCT CCAGGCCCTG CCCCTGCCC CTCAGCATGT CAGACACCCA CCTCTAGCT  
 GGTCTGGCCT CTTGAGTCTG AAACCCACCC CCAGCCCAAG CCCCCTCTCT GAGCCCCGCC  
 CAACCCATTT TCCGTTCCCA GAGCATGTTT TCGCCAACAA TGATGTTTCC TGTGACCACC  
 CCTCTAACAC CGTGCCCTCT GGGAGCAACC AGGACCTGGG AGCTGGGGCC GGGGAAGACG  
 CCGGCTCGGA TGACAGCAGC AGCCGCATCA TCAATGGATC CGACTGCGAT ATGCACACCC  
 AGCCGTGGCA GGCCGCGCTG TTGCTAAGGC CCAACCAGCT CTACTGCGGG GCGGTGTTGG  
 TGCATCCACA GTGGCTGCTC ACGGCCGCCC ACTGCAGGAA GAAGTGAGTG GGAGTTCCAA  
 GAGGAGGGTT GGTGGGGACG GGAAGTGGG GGTGGGGGTG GGAAGTGGG GGTGGGGGTG  
 TCATGGAGGT GAGGGCTGGT GGGGACGGGG AAGTGGGGTT GGGGGTGTCA TGAAGGTGA  
 GGGTTGGTGG GGATGGGTTG GGGATGTGG AGCAGGAGGA GGTGAGTTG GGGATAGGAC  
 TAAGGATGGA GTTTTGCGGG GGAGCAAGGT GGGAGGATGA GGTGGAGAG GGGAGAGTGT  
 TGTGGTAGGG AATGGGAAGG AGCCAAGGAT GGGTTGGATT TGGGGTTAGG AGCATATATT  
 TGTGAATGG TTTGGGATGG AGGTGGAATT GGGATTGGCT TTAGAATTGG GGGTGGGTGA  
 AAATCGGGCT GGGGTGGAAG TGAAGATAGC ATGGAGATAG GGTGAGATT GGGAGCAGAT  
 ATAGAATGAA GGATGGGGAT TGGAGTTTTG GGTGGGGTTG GAGATGGTTG GATTGGGCT  
 TGAGAATGCA TATGGTGATG GCTTCTGGGT AGGGAAAGAA TTAGGGTTGG GAATGGGATG  
 GGTGTTGGAAT TGTGACTGGG ATGGGGACAG GCATGGGATT GGAGACCAAG AGGGAGTTGA  
 GGATGGTTTG GGGACCGGGG GTGGGGATGG GGGTGGGGCT GGGGCTGGGT GTGGGGTTGG  
 GATTGGCGTT GGACGTGGAG ATAGAGATCA GGGTTGGTGG TGACCTGCCC CATCTTCTCT  
 AGAGTTTTCA GAGTCCGTCT CGGCCACTAC TCCCTGTAC CAGTTTATGA ATCTGGGCAG  
 CAGATGTTCC AGGGGGTCAA ATCCATCCCC CACCCTGGCT ACTCCCAACC TGGCCACTCT  
 AACGACCTCA TGCTCATCAA ACTGAACAGA AGAATTCGTC CCACTAAAGA TGTGAGACCC  
 ATCAACGTCT CCTCTCATTG TCCTCTGCT GGGACAAAGT GCTTGGTGTC TGGCTGGGGG  
 ACAACCAAGA GCCCCCAAGG TGAGTGTCCA GGTCTTCTT GATACCGACC CATCTCTGCC  
 GCCTTCCATC TTCTCCACT TCTCATTGTG TTCCTGTTTG ACAGTGCACT TCCCTAAGGT  
 CCTCCAGTGC TTGAATATCA GCGTGCTAAG TCAGAAAAGG TGCGAGGATG CTTACCCGAG  
 ACAGATAGAT GACACCATGT TCTGCGCCGG TGACAAAGCA GGTAGAGACT CCTGCCAGGT  
 GAGGACACCT CTCTTTATTG AGCAGATACA CACTGAGTGC CAACTCGGTA ACATGGAGCG  
 TTGCCAAAT CTGAGAATCC AGCAATTGCC AAGACAGTCA GGACCCCTGT TCTCACAGAG  
 CTCATACCT AGAGTAGTGG TGTTTAGTAG AAATAATGCT GAGCTGCTTA TGTCAATTTCC  
 AGTTTTTTAG TAGCCACATT AAAACAGGTA AAAAAGGCTG GCGCAGTGG CTCACACCTG  
 TAATCCCAGC ACTTTGGGAG GCTGAGGCAG GCAGATCACC TTTGGTCAGG AGTTTGAGAC  
 TAGCCTGGCC AACATGGCGA AACTCTGTCT CTAAAAAAA ATACAAAAAT TAGCCTGGCA  
 TGGTGGCGGG CGCCTGTAAT CTCAGCTGCT CAGGAGGCCG AGACACAAGA ATCACTTAAA

# FIGURE 3 (cont'd)

CCCAGGAGGT GGAGGTTGCA GTGAGCTGAG ATCGTGCCAC TCACTCCAAC CTGGGAGACA  
 GAGTGACACT TTTGTCTCAA AAAGAAAAAA AAAACAAGT AAAAAAGAAA CAGGTGAAGT  
 TAACTTAAT AACCCAATGT ATCCCAAATA CAATCATTTT AAAGTGTAAT TAATATAAAA  
 CAATTATGAA TGAGATACTT TACATCTTTT TCTTGTFTTC ATATTAAGTC TTTGAAAGTG  
 AGTATATATG TTATGCTGAC AGCACATCTC AATTTGGACT AGCTACATTT CAGGTGCTCA  
 GTAGCCACAT GTGGCTAGCA GTTACTGTAT TGGATGGCAC GGATCTAGAG GGAAAGATCA  
 GGGCTGTTTT GTATGGTTGG GCAGGTTGTG CACTGCATAA AGATACCATA TCTAATAGGG  
 GCACTCCGTG TTACAGATGT CAGTTTTGGC AGTTTTTCAG CGTGTGGTAG TTAAGTGTCT  
 TGTTTTCAACA AAATCTGTAA TATGACAGTT TTCTAGCAAG TGCTGGTAAA ATATCTTGAG  
 GAAGGAAAAG AGAAATCTGG TAGGTATTTT TACAAGAGAA TATTTAATAC AGGGGATTAA  
 TTGCAAAGCT GCTGGAAGGG CTGGAGGAAC AAAGTTAAAA AATAAAAAAC TCTGTGGTCA  
 AGAATCTGCA TAAATAGGGC AATTTAGAG AGTGGTAAAG GTTAACCCCA AAATAAACCA  
 TGGTTTTAGG ATAGTAAACA ATAAGGGCCA ATATTCAAAA AGGTGGTCAG GGGAGCCTCC  
 TTGGAGAGGT GGCATTTGAG CAGAGAATGG ATGACACAAA GAAGCTAAAC TCGTGAAGTT  
 TAAGGGGAAA GAAAAGGCAC GTGCAAAGGC CCTGAGGCG TAAGGAATTT GGCTGATTCA  
 AAGAAGAAGA GGAAACCAAT GCAACTGGAG AACAAAAGTG GGGGCAACAG TAGAAAGTGA  
 CGCTGGAGGT GTAGGCAGGG GCGAATGCTC TGCAAGTATT TCTTGGTCAC CAACACAGAG  
 CTTCCCTATG TTCTAATGGA AGCTGTATCT GTTGAGGAAG ACAGAATTTA AAATCAAAC  
 GTTACATCAA CCAGCACCTT TCTCTGTATT CAGGCTCCCA AGGGATCTAG AAGGACGTAA  
 GTTAACAAGC TCTCATTAGC AGGGTGTGTG TTTCAACAGT AGTTAGGAAG CTGGGGATTTC  
 AGGAGTACTC CAGTCCCATG GCTATGAAAA GCTCCCCCA AATTGTACAA ACCTGACAAA  
 TGCAACACCT CCCAGCTCT CCCCATTTCT TCTCTGTGCC CTGGGTGTGG GGGGGTGGGT  
 TGCGAGGGGG AAAAATTTTA ACAGAAGAAA GCACATCTCG GCCGGGCGTG GTGGCTCAGA  
 CCTGTAATCC CAACACTTTG GGAGGCCGAG GCGGGTGGAT CACTAGGTCA GGAGATGGAG  
 ACCATCCTGG CTGACACGGT GAAACCCTGT CTCTACTAAA AACACAAAAA ATTAGECGGG  
 CGTGTGGCA GCGCCTGTA GTCCAGCTA CTCGGGAGGC TGAGGCAGGA GAATGGCCTG  
 AACC CGGGG GCGGAACCTG CAGTGAGCCG AGGTTGCACC ACTGCACTCC AGGCTGGGA  
 ACACAGTGAG ACTCCGCTC AAAAAA AAAAGAAAAGA AAAGAAATCA CATCTCATTC  
 AAGTGGTGGC ATTTAAACT ATTTAGCCTT TCTGTAGGCA AGGTTAGTAT CTGTGTTTTT  
 CAGACCTCAA GGTGTTTTTT TGTTTTTTTT TTCATACCGG TGTGTGGTCT GGGTGTGGCC  
 ACTAAAAGCT ACAAGCAAGA AATAATAACA ACTACAACAA TACTAATACC AATAGTATAA  
 AAATAATAGC ATCTGGCTAA TTGCTGGACA CTGTTTTAAG TGGTTTGCAT GCCTCAGCTC  
 ATTAACCTAT TTACCTGTTA TTATTGGCCC TATTTTACAA ACAAGGAGCC AAGGCTCAGA  
 GCAGTTAACT AACAGCCTCT CAAAAGAAAC TCTGCAGAGA TATTAAATTT AAAAAATAAT  
 GAGAGAAATT AAACCACAG AAAGTTGAAA TTTAGAGGTA CAGGCAGCTA AGCTTGTTTG  
 CTTTGAACA GTGTCTGCTA CTGGGAAAAA GGCAAGTCTT GGCTTTCCTA ATAATTGATA  
 CCAGGACTCT GTGATTCATA TTTGCTATGC ATGTAAGTAA GAAATGAAGC CGGGTGCAAT  
 GGCACATGCC AGTAATCCCA GCACTCTGGG AGACTGAAGT GGGAGATCA CTTGAGCTCA  
 GGAGTTCAAG ACCAGCCTGG GCAACTAAAA ATTAACAAAA TAAAAATACT AATTGTTTTT  
 ATTTTAGTAG ATTTTATTCA TACCACCTAC ATCATTATTG TAGTATGTAC ATATTTATTT  
 CTTTTCTTTT CTTTTCTTTT CTTTTTTGAG ACGGAGTCTC GCTCTGTCAC CCAGGCTGGA  
 GTGCAATGGC ACCATATCAG CTCACTGCAG CATGCGCCTC CTGGGTTCAA GCATTTCTTC  
 CACCTCAGCC TCCCAAGTAG CTGGGATAAC AGGCACCCAC CACCATGCCT GGCTATTTTT  
 TTTTTCCGT AGAGATGGGG TTCCACCATG TTGGCCAGGC TGGTCTTGAA CTCTGACCT  
 CCAGTGATCT GCCTGCCTCG GCCTCCCAA TTGCTGGTAT TACAGGTGTG AGCCACCGTG  
 CCCAGGTGGG AGATAGACAT TTCTCTTAC CTCAAAACAG GGTCCACTCA AGCTACTTTT  
 CATTTCCTC ATAAATATTA GCCGAGTGGC TATTTTGCAC CAGGAATGGT TCCAGGTGCT  
 GTGGATATGG CATCAGGCAA AACAGACCAA AAACCTCCTG CCGCGTGGAC CTCATGTTCC  
 CCAAGTGGA GACAGGCAAT AAAGAGATAG ATAAATATGT AGTAAATTA AAAAAA  
 AATTAGCCGG GTGTGGTGGC TTGCACCTGT AGTTCCAGCT ACTTGGGAGG CTGAGGTGGG  
 AGAATTGCTT GAGCCCAAAC GTTTGAGGCT GCGGTAAGCC ATGACTGAC TGCTGAGTC  
 CAGACAGCAG CCTGGGTGAC AAAGCAAGAC GTTTTTGTC AAGAAAGAAA AAAAAAGAC  
 GAAGGGAGGA AGGAGAGAGA AAGGAAGGAA GGAAGGAGAA AGAAAGGAAG GAAGGAGAAA  
 GAAAGNAGG AAGGAAGGAG AAAGAAAGGA AGAAAGAGAA AGAAAGAAA AGAAAGAAA  
 AAAGAGAAA GAAAGAGAG AGGAAGGAG GAAAGAGGA AAAGAGGGA AAAAAAGACT  
 GTTGAAGAGC AGTGAGTATT ATTATAGGAG GGTAAATTATA GGGAGGTATG GGAATTGAA  
 GACAGGAAAC ACAAATTAGT CCAAGCGAAT GGATTTCTAT TGGGAGTGAT TCTGCCCTA

01  
 02  
 03  
 04  
 05  
 06  
 07  
 08  
 09  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100

# **FIGURE 3 (cont'd)**

GAAGACACTG	GCAATACCAG	GAGACATTTT	TGTTTGTAC	AACTATATGG	AGGGGCATTA
CTGGCAACTA	ATGGATAGAT	GCCAAGTGTG	CTGTTCAACA	TGCTATGATG	CACACGGCAG
GCCTCCACAA	CAAACCATT	TCCAGCTTCA	GATGCCCACA	GTGCCCAGAT	CGAGGAACCC
TCATCCAGGG	GCTGAGAACC	GTATTTTTGC	AGAAGGGAGG	TATAAGGATG	GGTTGGTGGA
GAATGGGGAA	GGAAGGTGTG	TGTCCAGTAA	GAGAAATAAG	GCCTGCACAG	GCTGGAGGGG
AGAGTGAGAG	AGAAAGGGAG	GCGGAGAGAT	ACACGATGAG	GGAGACAGGC	TGGAACAGAA
AGTAGAGACG	AAGATTGAG	ATGTGGAGAG	GAAGGGTCAC	AGACCCCCC	GAAATGATGT
GTGGACAACA	GGAATCTGGA	AGAGGAAGAT	GGAGTGAGA	GTGACAAATG	GGGTCTAAAG
GTTGAACTTG	GAGGCCAGGC	ATGGTGGCTC	ACGCCTGTAA	TCCCAACACT	TTGGAGGCTG
AGGTGGGCGA	ATCACTTGAG	GCCAGGAGTT	CGAGACCAGC	CTGGCCAACA	TGGTGAAACC
CCGTCTCTAC	AAAAAAATA	CAAAAAATTA	GCCGGGTGTG	GTGATGGACA	CCTGTAGTCA
CAGCTACTTG	GGAGGCTGAG	GCAGGAGAAT	TGCTTGACC	CGGGAGATGG	AGGCTGCAGT
GAGCTGAGGT	CAGGCCACTG	CGCTCCAACC	TGGGCAACAG	AGTAAGACTC	CATCTCAAAA
AAAAAAAAGC	TGGATTTGGA	GTGAAATATT	AATAACATTC	TCCCTCTCTC	TCCTTTTGCC
TGTGTCTCCA	TCTCTGTCTT	TTTCTGCATT	TCTTCATCTC	TGTACTTTCC	ATCTCTGTGT
GTCTGTTCCC	ATCTGCTTCT	CCATCTATGG	GCATCTCTGG	GTCTCTCATG	TCTCCTTCTG
CCCACTTTGC	CACATCTCTG	CCTCTCTCAT	GCCCCCTTT	CTCTCCTGCA	GGGTGATTCT
<u>GGGGGGCCTG</u>	<u>TGGTCTGCAA</u>	<u>TGGCTCCCTG</u>	<u>CAGGGACTCG</u>	<u>TGTCTTGGGG</u>	<u>AGATTACCCT</u>
<u>TGTGCCCGGC</u>	<u>CCAACAGACC</u>	<u>GGGTGTCTAC</u>	<u>ACGAACCTCT</u>	<u>GCAAGTTCAC</u>	<u>CAAGTGGATC</u>
<u>CAGGAAACCA</u>	<u>TCCAGGCCAA</u>	<u>CTCC7GAGTC</u>	<u>ATCCCAGGAC</u>	<u>TCAGCACACC</u>	<u>GGCATCCCCA</u>
<u>CCTGCTGCAG</u>	<u>GGACAGCCCT</u>	<u>GACACTCCTT</u>	<u>TCAGACCCTC</u>	<u>ATTCCTTCCC</u>	<u>AGAGATGTTG</u>
<u>AGAATGTTCA</u>	<u>TCTCTCCAGC</u>	<u>CCCTGACCCC</u>	<u>ATGTCTCCTG</u>	<u>GACTCAGGGT</u>	<u>CTGCTTCCCC</u>
<u>CACATTGGGC</u>	<u>TGACCGTGTC</u>	<u>TCTCTAGTTG</u>	<u>AACCCTGGGA</u>	<u>ACAATTTCCA</u>	<u>AACTGTCCA</u>
<u>GGGCGGGGGT</u>	<u>TGCGTCTCAA</u>	<u>TCTCCCTGGG</u>	<u>GCACTTTTCA</u>	<u>CCTCAAGCTC</u>	<u>AGGGCCCCATC</u>
<u>CCTTCTCTGC</u>	<u>AGCTCTGACC</u>	<u>CAAATTTAGT</u>	<u>CCCAGAAATA</u>	<u>AACTGAGAAG</u>	

661040 040199

# FIGURE 4

KLK-L 3

CTTGAACCCA GGAGGCAGAG GTTGCAGTGA GCTGAGATCG CGCCACTGTA CTTGAGCCTG  
GGTGTGAGAG CAATACTCCG TTTTGGAAAA CAAACAAACA AACAAACAAA CAAAAACAG  
ATGGAGCAAC TGAGAGAGGT CTTGTGACTT GCCCAAAGTC ACACACCTCA TCACTAATCA  
CACCTAATCA TTGAGATTG GACACACATG GTTCAGTTCC AGAGTCCATG CTCCAAACCA  
TGACGACACA GTGAGAGAAC ATTCAGGGG AGCCCAGACC CAGCTTCATA ACCAGGCCTG  
TGAGCAGGAG AAAGTGAAG GGATCGTAAG TGCCCAGGGG AGGCAAAGAT GGACTCTGCC  
TGAGGATCTC AGAGATTTC TGGAGGAGG AGAATTGAGG TTGGGTGTG AAGGATGAGT  
GGGAGTTCAC CAGGAAAAGA AGGATATGGA GAAAGACAT CACTCATTCA ATGAACATCT  
CCTGAGGACT TCTGCAAGCC CTGTTCCGCC TGGAACGGGG TGATGCTGGG ACACAGAGAT  
GAGTCAGACC TGGGCCCAGC CCTCCAGAAG CTGTCCACCT GGTGAGAAAG AATGATGAGG  
AGAGAGGCAG GGAGGATGGG GTGATGGAAG GGACAATGGG GTGGGGGGCA GGGAGATGGA  
TGAAAAAAT ATATAGCAA TGTTCTCAGG ATTTGGCAA GATCAGGATG TATTAAGAGA  
GAGCACAGGG CACTTGCTAC CTGGAAGGTT GGGCACCTGG GTCTTGGGT GGTGGAGCCG  
TGGGGAAGGG GGCAGGTAT GACAAGAGTG GGTAAATCCA GATGGAACCA GATTTCTCAA  
CATTCTAGGA GAGGGCCTTG TCCTTGTGGG AAGAGGCCCA AATCCCCAGG GCAGGGAAGG  
TTCTGCAAGG TGTGTAAACC TGTGCAGCTG CCTGTGGTCT CTGCCTCACT CCACCTGGAT  
TTCCCTCAAT CTTTCCCGTG TTCTGTCTCC TCCTCCCACT CCTGCTCTCA TCTTGGGTCT  
TTCTGTGCTT GTACCTCCCT CTCTTTGTAT CTTTGTCTCT TGTGTCTGAG TCCTGACTCT  
GTCTTCCACC CCTCGCTCC TTTCTGGGTG GTCCCCCTGC ACATCCCTCC AGGCTGCGGT  
GGGAGGTTGG TCTCTGCACA CCACTGCTTT ATCCAAAATA AACCTGCTGG ACCCCAGGAC  
CTTAGGCTTC AAGGATCTCC CTCCTTTTTC AGGACACAAA AGATTCTGTA TCTTGTAGGG  
TAAGGTGATG AGGAATGAGG TCTCCCACTC TGAAGAGCCC AGAGGAGGTG CCCACAAGCT  
CTCCACACCC CCAGCACTCC TCCTCCATTC AGTCAAGTCT TGGCCAGGCA AGCCGCCAGT  
TCATCCCAA AGGGGGGTCC CCCTGCACCT ACCTCCTCTC CCAAGGCGCC TGTCACAGCC  
CCAGGGCTTC CCCCTCCCC AGGTACATTT CCCAACCCCG ATTAATCACA GGGGCGGCCC  
CATGGAGGAG GAAGGAGATG GCATGGCTTA CCATAAGAA GCACTGGACG CCGGGTGCAG  
GTTCCAGGAT CCAGGTGCC AGGGGTCTAT AAGCTGGGAG TCCTGTGTGC TCTGTCTCT  
CTGCTGGCAG GTGAGGCTCC CAGGCTGGCT GCCECTTCAG GGCTGTAGTA AGGTACCTTT  
GCTCTTCCCT CCCATCCAG GCTTGTGCTT CCTGCTCTCT AGGCTTCTCA GCATCCTCTC  
CCTGCCCTCC CAGCCTGCTC TCGCTGACC CTTTGTCTCC TCATCCCCAC CCCAGGGCAT  
GGCTGGGCAG ACACCCGTGC CATCGGGGCC GAGGAATGTC GCCCAACTC CCAGCCTGG  
CAGGCCGGCC TCTTCCACT TACTCGGCTC TCTGTGGGG CGACCTCAT CAGTGACCGC  
TGGCTGCTCA CAGCTGCCCA CTGCCGCAAG CCGTGAGTGA CCCAGGCTGG CCATGCTGGG  
GAGGGACAGA GGCTGGGGGT CAGGAGAGGG TGAGGGGTGC TTAGGGCCAG AAGTGCGGAG  
CCTCCACTTC TGATACCACA AGTTCAACTC TTAGAAGTAG GAAGGGTAGC CTCCCAAATC  
CTAAAATTCT AGAGACCAGC AATATCTCAT TTGAGAAGTC TAAGATTCTA AACTTAGGCT  
CTTCGAATCC GAGACTGACC CAGAGAAATC CAGAATCGTA GAATCCTAAA ATCTTGAATT  
TATGAAATTC TGCAATAGCC TCAGCAAATT TTAGAATCAT AGATTGCGAG ACTATTAGAA  
TCTTAGCAGT CTGGGTGAGC ACTGCCCAGA GGAATATGA TGCCAGCCAC ATGTGTAAGT  
TTAAATTTCT GGTGGACACA TTTAAAAAAT AAGGAATGAG TAAATTAAT TCTAATAGAT  
TTAACTTGAC ATACCCAAAA ACTTATTTTG ACATGTAATC AATTTTAAA TACGTATGAA  
CGATACAGTT TACTTTTGTT TTGGTACTAA GCCTTTGAAA TCTGTTCTGT ATTTTACACA  
CATAGECTGT TACAAAATGG ACTAGCCACA TTTCAAGTGT TCAATAGCCA TAATGGGTAG  
TGTGATCCTA GAATCTTAAA TTCAGAGCTT TCTAGATTCA TTGAATATTG AAATCAGAG  
TACTAGAATC TTGATTACAG AGTATCCTAG AATATTGAGA TTCAGATAAT TCTGTAGTCT  
TAAACTATTT GAATCCCAGA CTCTTAAATT TCTAAGGTTA TAGATTATA GAATGATGAG  
ATTCTAGTCT TCTTTTCTTT TTTTCTTTT TTTTCTTGGT ACAGAGTCTC CCTGTATCTC  
CCAGGCTGGA GTGCAAGTGGG ACAATGTCAG CTCAGTGCAA CCTGTGCTCT TCGGGTCTAA  
GCAATTCTCC TGCCCTCAGCC TCCTGAGTAG CTGGGATTAC AGGTATGCAC CACCATGCCA  
GGCTATTTTT TTTTTTTTT TTTTTTAGT AGAGACGGGG GTTTCACCAT ATTGGCCAGG  
CTGGTCTTGA ACTCTGACC TTGTGATCTG CCCGCTCGG CCTCCCAAAG TGCTGGGATT

60427366 646156



# FIGURE 4 (cont'd)

ATCTCGGCTC ACTGCAACCT CCACCTCCTG GGTTTTAAGT GATCCTCCTG CCTCAGCCTC  
 CCGAGTAGGT GGGAGTACAG GTGTGCAACA GCATGCCAG CTGATTTTTT GTATTTTTCAG  
 TAGAGACGGA GTTTCACCAT GTTGCCAGG ATGGTCTCAA TCTCTTGAGC TTGTGATCCG  
 CCCGCCCTCAG CCTCCCAAAG TGCTAGGGAG TTATATATGC ATCTCCTCTT ATCTCTTGGC  
 TCTCTGCATG CATCTTTCTG TTCTCTTCC TTCTTTTCTT TTTTTTTTTT TTTTTTTTTT  
 TTTTTTTTTT TTTTTTGAGA CGGAGTCTTG CTCTGTCTCC CAGGCTGGAG TGCAGTGAGC  
 AGTCTCGGCT CACTGEAAEC TCCACCTCCC AGGTTCAGT GATTCTCGTG CCTCAGCCTC  
 CCGAGTAGCT GGGATTACAG GCGCCTGCCA CCATGCCTGG CTAATTTTTG TATATTTAGC  
 AGAGATGGGG TTTCACCATG TTGGCTGGGC TGGTCTCAA CTCTGACCT CAAGCGATCC  
 GCCGGCCTCG GCCTCCAAA CACTGGGATT ACAGGCATGA GCCACGGTGC CCGGCCAGCC  
 TCTCTCTCTA CTGGCCCTC TTCTCCTTG TCTCCATTG TTTCTCTTGT GTGCTATGAC  
 TGTCTGTCTG TCACTGTCTC TTGTCTCTAT CTTGAGAGT CCTAAATGTG GCTCCATTGG  
 TCCTTTGGAA AAGCTGCAGG GAGGACTCAG GGCAGTGGG TGCTGAGTGT GTTGGAGACA  
 GTTGACAGT CTTGACAGT CTCTTCCCTG ACAGCGCTGT TTCCAGTCAC ACTGCAGTGT  
 GCCAACATCA GCATCCTGGA GAACAACTC TGCTACTGGG CATACCCTGG ACACATCTCG  
 GACAGCATGC TCTGTGCGGG CCTGTGGGAG GGGGGCCGAG GTTCCTGCCA GGTGAGACCT  
 TACTCTGGGG AAAATGAGGC TGTCCTGCCA AGTTTCTAG GATTAGGGG AGCAGAGGGG  
 TCGGCCCCCA GCCTTCTGG GTCAAAATGA GAAGGAGACT GGGATACCTG GTTCCTGGGA  
 GAGGACGGGA CCAGGGCCTG GACTCCTTAG TGTAAGAG AAAAGGTCTG GAGGTCCAGA  
 CTTCTGGATC TACAGGAGGA GTGGGCTGGG CGTCCAGAGT CTGAGTCTC GGGGAGGAGG  
 AGGTTAGGTC CTGEGGGGAG GTGGGCCCTC TGAGCTTTTA CTCTGGGTC TGAGGAAGAA  
 GAGGCTGGAG ATGGAGGACT CTCGGATGTT GGAGGAGGAA GGGGCTGGG CCTTTCTGGG  
 AGGGAGGAAG TGGECEGTGT AATTGTCATG AAGAGAGTGG CCTAAGAGTT CCTCTGECCT  
 TCTCTCGCGT ACAGGGTGAC TCTGGGGGCC CCCTGTTTG CAATGGAACC TTGGCAGGGG  
 TGGTGTCTGG GGGTGTGAG CCTGTCTCA GACCCCGGGG CCCCAGTC TACAGCAGG  
 TATGCACTA CTTGACTGG ATCCAAGAAA TCATGGAGAA CTGAGCCCGC GCGCCAGGG  
 GGCACCTTGG AAGACCAAGA GAGGCCGAAG GGCACGGGT AGGGGGTCT CGTAGGGTCC  
 CAGCCTCAAT GTTCCCGCC CTGGACCTCC AGCTGCCCTG ACTCCCTCT GGACACTAAG  
 ACTCCGCCCC TGAGGCTCCG CCCCCTCAG AGGTCAAGCA AGACACAGTC GCGCCCTC  
 GGAACGGAGC AGGGACACGC CTTTCAAGC CGTCTCTAT GACGTACCG ACAGCCATCA  
 CCTCCTTCTT GGAACAGCAC AGCCTGTGGC TCCGCCCAA GGAACCACTT ACACAAATA  
 GCTCCGCCCC TCGGAACCTT GCCCAGTGGG ACTTCCCTC GGGACTCCAC CCCTTGTGGC  
 CCGCCTCCT TCACCAGAGA TCTCGCCCT CGTGATGTCA GGGCGCAGT AGCTCCGCC  
 ACGTGGAGCT CCGGCGGTGT AGAGCTCAGC CCCTGTGGC CCGTCTCTG GCGTGTGCTG  
 GGTTTGAATC CTGGCGGAGA CTTGGGGGGA AATTGAGGGA GGGTCTGGAT ACCTTTAGAG  
 CCAATGCAAC GGATGATTTT TCAATAACG CGGAAACCT CA

5' 10' 15' 20' 25' 30' 35' 40' 45' 50' 55' 60' 65' 70' 75' 80' 85' 90' 95' 100'

# FIGURE 5

KLK-L 4

ATTAAGAAGG	ACCCAGACAT	ACAACCTCTA	AATTCTGAGG	GTCATCCAGT	AGAATATTCC
ATATATGTAT	ATATGAAATA	TCCTATATCT	GTGCTGTCCA	ATTATCCACT	AGCCCCCTTCA
GGCTATTGAA	CATTTGAAAT	ATGGCTGGTG	TGACTTAAGA	ACTGAATTTT	TAATTTAGTT
TTACTTTCATT	TTAATTAGTT	TAAATTTTAA	TAGCCACATG	TAGCTAGTGG	CTACCATATT
AAACAACATA	GGTCTGGAGA	AAGGACTGTG	CAGAGAGAGG	AAATAGCAAG	TATAAAATGT
CTAGTATGGG	GGCATCCAAG	ATGATTTTAA	TTCTTCTTTT	CTTTAAATGC	CTGGTGTGTT
TGAAGAACAG	GGCCATGAGG	CTGGACTAGA	GGAAGTCAGA	AGAAAGAGGT	TGGAGATGGG
TGCAAGAGAG	CTGGCAAGGG	CCAGACAGCA	CAGAGTCCTG	CACACCTTGG	GAAGGCTTTT
TGGATTTTAT	TTTAAAGAAA	GTTGAGCCTG	GGAACAACAT	CTGACTTTCT	TTGTTTGAAG
AGTCCTCAGC	CTACTTTGAG	AAGACTGGAT	CGGAGGGATG	TAAAAGTGGA	AGGATTTAGG
TTAATGTTGT	AGTCATTTGG	GCTACAGAAG	ATGGGGCATG	GACCAAGATG	GTGGCAGAAG
TGTGGAGATA	ACTGGATATT	TGGGAGATAA	AACCAATAGG	AACTGGTTGT	GAGTGATGAA
GGAAAGAAGA	GAAGCAAAGA	TGACTCCCAG	GTTTGGGGCT	GAGCACTGAG	GTGGGAAATA
CTGGAGCGAA	CAGTTTGTAT	TGAGAAGAAT	CAAGTTGGGA	ATACAAAGCT	TAAGATGCCT
GTAAGGCATC	CAAATCAACA	GTGTTTGAGT	TTTGAGCTTA	AAGAAGAGTT	CAGGGCTGGA
GATGATTAGC	CTATAGCTGG	TATTTAAAGC	CATGGAGGCA	ACCAGTATAT	ATGCAGTGAA
AGGATAGAGA	GATGGGTGGA	AAGATGATTG	GATGGATGCA	TGGATGGATA	TATGGATAGA
TGGATGGATG	GATGGTTGGA	TTGGATGGAT	GGATGGATGG	ATGGATGGAT	GGATGGATGG
ATGGATGGAT	GAATAAATGG	ACCAGTGGAT	GGAGGGACAG	ATGAGTGGAT	GGATGGTTGG
ATGGATGGAT	GGATGGATGG	ATGGATAGAT	GGTTAGATGA	CTACCTAAAT	GGATGAATGG
ATAGATGGAT	GAGTAGACGG	ATGGACAAAT	CAATAGGATG	AATGGGGGAT	GGATGATTGG
ATAGATTGAT	GGATAGATAT	TGCCTAGGTG	GATGTGTAGG	TCAGTCTCAC	TTCTACCTCC
TGAAATCCAT	CTTCTGGTAG	AATGATATAA	AAAATGCATG	TGGAGAGAAA	GTCAAGCTCC
TGCTTACCTA	TCAGCAACAT	CCTCATTTTG	TGAACCTCTC	TGTTAACCCC	CAGTGGAGGA
TTTGGTACTT	CCTGAGAAAA	TAATGTCACC	CCTTTGCCCT	AATTCATCTC	CACTTGGTCA
AGAATAGCAA	CTGCCATAGG	TCGGCAAATT	CATCTTCAGT	TCCTGGTCAC	CCAGGGCAAT
AATCCGACCC	TTACCCCAA	CCCAGAAACC	ACAACCCAG	GGCTCCTCTG	CCCCCTGGAT
CCCAGTTTTC	TAACAATCTC	TCTTCTTTAC	CAGGTGTCTC	CCAGGAGTCT	<u>TCCAAGTTTC</u>
<u>TCAACACCAA</u>	<u>TGGGACCACT</u>	<u>GGGTTTCTCC</u>	<u>CAGGTGGCTA</u>	<u>CACCTGCTTC</u>	<u>CCCCACTCTC</u>
<u>AGCCCTGGCA</u>	<u>GGCTGCCCTA</u>	<u>CTAGTGCAAG</u>	<u>GGCGGCTACT</u>	<u>CTGTGGGGGA</u>	<u>GTCTGGGTCC</u>
<u>ACCCCAAATG</u>	<u>GGTCCTCACT</u>	<u>GCCGCACACT</u>	<u>GTCTAAAGGA</u>	<u>GTATGTGGGG</u>	<u>GCCGGGGGAG</u>
CATGGGGTAG	GGATGAGAAT	GGGACTGGGA	TTGTGGATGG	GGTAGAGTTG	GATTTGAGGA
TGGAGTTGGA	GTTAGGGTTG	GGGATGGACA	TGGGAGTGAG	AATGAGGTTT	GGGGTTGAGA
TATGGGGATT	GGGTATGGGA	ATAGAATCAA	AGTAGGGGAT	TTGGATGGGA	TTGAAGTTGA
GGATGGGGGA	GATGTATTTG	GAGATGAGGA	AGGTAGGATG	GAGAAGAAGT	TAGGTGGGGG
ATGGGAAGAG	GTTGGGGCTG	GGATGGGGAT	GGAATGGGC	TCATCTTCTT	TCCTAACCAC
CTTCTTTCTG	CACCCACAGG	GGGCTCAAAG	TTTACCTAGG	CAAGCACGCC	CTAGGGCGTG
TGGAAGCTGG	TGAGCAGGTG	AGGGAAGTTG	TCCACTCTAT	CCCCCACCTT	GAATACCGGA
GAAGCCCCA	CCCACCTGAA	CCACGACCAT	GACATCATGC	TTCTGGAGCT	GCAGTCCCCG
GTCCAGCTCA	CAGGCTACAT	CCAAACCCTG	CCCCTTTCCC	ACAACAACCG	CCTAACCCCT
GGCACCACCT	GTCCGGGTGTC	TGGCTGGGGC	ACCACCACCA	GCCCCCAGGG	TATGCACCCA
CACAGGTGGC	CTGAGGCCCC	ATAGGAGTGG	CTGGGGAAAC	AGGGGCAGAG	ATGGGAGGGA
AGGTCTGAGG					
TAGGTTTCCTT	TATATATAAA	AATATAAATA	AGTAAATAAA	TATATATATT	TAAAGTTAGC
TGTATCCTTT	ATATAAATAT	AAATTCATGA	ATATATAAAA	ATATGAGTAT	ATAAATTCAT
GAATATATAG	AAATATAAAT	AGATCTAATA	TATGAATATA	TTATATGATG	TATATTATGT
ATTATATAGT	AATATAATTA	TATATTATAC	AAAAAGTATA	CAAAATTAAAT	GTATTTTATA
AATTATAAAA	TTTATCAATT	ATGTATTTTA	AATATGTATT	TCTGCATAAT	GTATATATTA
TATATAATCT	ATATTTTAAAT	TATATATTAT	AAATGTATTT	TATAAATGTA	TACATTTATA
TATTTATATA	CTGTAAATGA	ATTTTATCAT	TTATAATATA	TAAATCATAC	ATATAAAATG
TTTATATTTT	TATAATTTAT	AAAATGTTTA	ATATATTAAA	TATGGTTATT	AATGAAATGT
CTAATAATTC	AATGTAATAA	TTAATTCTAT	ATCATTACTT	AGTAAGTATA	ATACATTATA
TATGTGAATA	TAAAGTTGAT	GTATATAACG	ACAAGAGCCC	TTTGCATCTC	CCTAGCAATC
CCTGACTCTC	TCCCAGCCTC	ATGTTTGTAT	CTTTCTCCTC	AACATGCCCT	GTCTCTCTTC

0123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100

[illegible]

TACCACTTET	ATCEAACTET	CCCGTAACTC	TTCCCATCCC	TGTTCTGTCT	TTTCCCATGT
TTAATTCTET	ATTTCTGAG	ATCTCCCTAT	TCCAACATCCC	TCTCTCEAAC	TTTCTCTGCG
CACCGCTGGC	TCCACCACTC	TCCTTATCAA	CCTTCEATTG	TCTTGTCCCT	TCECTCCTTG
TCCTTCCCTC	CACCTTTTCT	CTCATCTCTC	CCTTGGCCTC	TCTCCCAGT	CCCTCCATAT
TTCTGTCACT	TCGGTTGCTT	TACCCAGATA	GGTGCTCATC	TCTTCTCECA	TCTTTCTCTT
CCCATCTCAA	TTTTCTATCT	ACTCTTTACC	CATTCAACTC	GCCTATTCTA	CCTTCATCCC
ATATCTTATC	CAGGTCCGAT	ACCTTAGACC	TTCTCTTCT	TCTCCCAGT	GAATTACCCC
AAAACTCTAC	AATGTGCCAA	CATCCAACCT	CGCTCAGATG	AGGAGTGTG	TCAAGTCTAC
CCAGGAAAGA	TGACTGACAA	CATGTTGTGT	GCCGGGACAA	AAGAGGGTGC	CAAGAGCTCC
TGTGAGGTGA	GCGCCGGGAG	CTGGTGGGTG	CCTTGGACAG	GATAGAAAGC	CAGAATGGAA
GTGACAGATG	CTGGGGAAAA	AGCTTTGTTT	CCAGCCTTAG	GGGAACCAAT	CTTTATAAGA
TACAATGTCC	CCTCACATAG	GAGGTCAAGA	CAAAAAGGGG	TACCCAGGGA	TGGCAGGAAAT
AATTCATCAT	AAGCCCCAGC	TTTGACTGAG	TGGCTGCCAA	GATCCCTGTG	TTGAGATGCA
TAAAGGTTGG	TATTTCTTCA	CTTGAGTAGT	ATAGACAACC	AACCTCAACT	GGCTTAAACA
AAATGCAAGC	TTTTGTAACT	GAATAACCAG	GTGTCTGGC	TTTAGGCACA	GATGGATCCA
GGTATGCAAA	TTGTGTGTTT	GGAATCTGT	CTTTCTTTTA	ACTCTCAGCT	CTTCTTTATT
CTGTTTGGC	TTCACTCTCG	GTTAGATTCT	TCCCATGACA	AGATGGCCCC	AGCAGCTTTG
AGCTTACAT	CTACCCCTCA	GGCAACCCTA	TTAGAAAGAG	AACCTCTCTT	TTCCAATTAGT
TCACACAAAA	GTCTTAAGTA	TGATTTCTAC	TAGGCTGACC	TAAGTCATGT	GTCTTGAGCC
ATCACTECAC	CAGAGCTGTG	GGATTCTCTG	ATGGGCCAAG	CCTGAGTCAC	ATAGTTTACT
GTGGGTGTGT	GAGAGGGGCA	GGGACAAACT	GCATGGATTG	GAAGTGGAGA	AGGGCAGTTC
CCCAAATGAA	AAATCAGGA	GAGGCTGTTA	CCAAAATAAG	GGGAAATGGC	CAAGTACAGT
AGGATGTGCC	TGTAATCCCA	GCACCTTTGG	AGGCTGAGTG	GAGAGGATTA	CTTGAGCECA
GGAGTTTGAG	ACCAAGCTGG	GCAACATAGT	GAGACTGTGT	CTCTGACAAA	AGAAAACAAA
GTTTTTAAAT	TAGCCAGGTG	TGGTGGAGTA	CAACTGCAGT	CCTAGTTACT	CGGGAGGCTG
AGGCAGAAGG	ACTATTTGAA	CCCAGAGGTT	CAAGGCTGGA	GTGAGGTATG	ATCATGCCAC
TGCATCCAG	CCTGGGTGAT	AGAGEAAGTC	CCTGTCTCTA	AAACAAAAG	AAATAAATAG
AGCAAGACAC	TGCTCTAAT	AAATAAATAA	ATAAAAATFT	AAAAATGAAT	GTTTAAATFT
TTAAAAATAA	GAGGAAATGG	ATACTACATG	AGCAAAAAAT	AGCCTTCATC	AATAAAGAG
TTGAGATTGG	ATTCAAGTGA	AAAGAGTATG	ATACTATATT	AATGATATGT	GCCTTGATGG
ATTAGTGATG	TCTGCTTGG	GCCCAGGAAG	AGAAATAGAC	TTACACGTGT	GTGTCATACC
CTGCCCAGAT	ATGATGGGT	TCACTCAATG	GTGAGAGACA	CAAAATGAGC	TTAAATAGGA
GCAGGGCTAG	CTGTGTGGG	GCAGGGGTG	ATTTAGTACC	AGGGAACAAA	AAATGGGTAT
GAAGTAAGTT	GTTACCATT	TAATGAAACT	GAGGAACAGA	GA AAAACACA	GAAATTTCTC
TGTGTCTCTC	TTTCTCTGG	CCTATCTCTG	TCTTTCTGTC	CCTATTCTG	TCTCTTGCTG
CTGTGCTCTC	TGTGTTTGTG	TTCTGTCTG	TTTCTCACTG	TCTTCATTG	TTTCTCTCAC
ACTGTGTGTG	TCTGACTCTG	CCTCTCTGAG	TCTCTCTCTC	TGTGTGTGTC	TCTCTCCATC
TTTCACTCTC	TCCCCACACC	TCCCTGTCCC	TGCCCTGTTT	AGCCCCAGCA	AGGACCCACC
TCTCTCTCTC	TTTCTTTCCC	CAACTCAGGG	TGACTCTGGG	GGCCCCCTGG	TCTGTAACAG
AAACATGTAT	GGCATCGTCT	CCTGGGGAGA	CTTCCCATGT	GGGCAACCTG	ACCGGCCCTG
TGCTACACCC	CGTGTCTCAA	GATACGCTCT	TGGGATCCGT	GAACAATCC	GA AAATATGA
AAACCCAGCAG	CAAAAATGGT	TGAAGGGCCC	ACAAATAA		



## FIGURE 6

KLK-L 5

GTCATATTACATGAGGGCTCTGCTAGACTCCGAAAAACAAAAACAGCAC  
AAAGTTCCTTGTCTGTGACTCATTCTCTCTCTCTTTCTACCATTTT  
TCCTTCCCTGTGTCTTTTTTTTTTCTCTCTGTGGGTTTTATTAAAGCAAT  
AGAAGTTCTTAGCAAAGAAAACTTTATGGAATTAGATTGATCCACTTCA  
TATGTACATATATGAACTCAGTTCAGAACTCTCTTCTACCCCTGCCTGA  
TCACCTATTTGGAAGTCTGTTCCTTCAACTCTTCTTCTTTCTGGGACT  
CTTTCTAGCTTGGGCTTCCTGCCCCCTCCCGTCCACTCTCCTGCTTTCACA  
GCCTCTCCTTCCCCCTGCCCCCTCCCCTGCACTGCATGGGGATGGGCCCCA  
GGTGTCCAAGGTCTCCCCACCCTCCTTTGTCACTGGAGTCAGGATTAGAA  
CCCAGCTCCCTAGTCACCTTGAGTCATCAGTCTGGGGCTGCTGACGGGC  
TTGCAGAGGAGAGAGGGAGTGGGGCTGGGTCTTCCCACCCTGGGTCTTTT  
CCTCCTTCCCCACTCCGTTTAGCTGTAAAGCTCAATTAAGTGTGATTAGC  
TGAGAAGAGTTTCTGCAGAATTAGAGCACGCCCCACCCTGTCTTCGTGG  
TCCCCCTTCCCTTAACCCGAAACTGGATGGGCCAGGACAAAGAGAGTTAA  
GAGCTTTGTCACTGGTCTGTCTGGAGCGACAGATGGAAGGAAAGGGACCG  
GTTGAGCAACATGACAGGTGGCTGAGGAGCCAGGTGCAGAGTGGTAGAGT  
TGGCTGGCGGAGTGGCCAGCACATGAGAAGACAGGCAGGTAGGTGGACGG  
AGAGATAGCAGCGACGAGGACAGGCCAAACAGTGACAGCCACGTAGAGGA  
TCTGGCAGACAAAGAGACAAGGTGAGAAGGAGGTAGGCGACTGCCAATGA  
GGGAGTGACACACAGGGGAGCAGGTAGAGAGAGGACAAGCAGGTATCCC  
CTTGGTGACCTTCAAAGAGAAGCAGAGAGGGCAGAGGTGGGGGGGCACAGG  
GAAAGGGTGACCTCTGAGATTCCCCCTTTTCCCCCAGACTTTGGAAGTGAC  
CCACCATGGGGCTCAGCATCTTTTTGTCTCCTGTGTGTTCTTGGTGAGTTC  
TCCCGGAGCAGGGAGAGGGCAGGACTGCGACTGGATCCCTTCACCCCCAT  
GAGGAGGCCCCACCACCCTCCCCTCTCAGTCTTGCCCCCAGCCTGGTG  
GTGAGGAGGAGAGGGGCTTCTCTGTGCTCCATTTACCTGCAGCTCTCA  
GGGTACTGCTCACCTCGGTCTCCCCTATTTTTGATCCCTCTTCCCTTCT  
GTCCCTCTCTGAATCTCTGTCTCTCCATTTCCCTCCTATGTGTAAGCATC  
TTTCTCCCTGGGTGTCTTTGATGTTTCATGGTCTTTTTCTATCACTGGGT  
CTCTCTCTCTTCTCTCTCTTCTCGTCTCTCTTCTCCTCTCTCTCTCC  
TGCCTGTTTCTCTCTCTCACTCTGTGTCTCTCCATCTCTGTATCTTTT  
CTTCTCTCTCTGACCCATGCCCTGTCTGTCTCCAGGGCTCAGCCAGGC  
AGCCACACCGAAGATTTTCAATGGCACTGAGTGTGGGCGTAACTCACAGC  
CGTGGCAGGTGGGGCTGTTTGAGGGCACCAGCCTGCGCTGCGGGGGTGTG  
CTTATTGACCACAGGTGGGTCTCACAGCGGCTCACTGCAGCGGCAGGTA  
AGTCCCTTCTGGGGTGGGCGAAGGGAGGACTATGGGAAGGCAAGCGCTG  
GGGGTAGGATCACAAGGGAGGGTGGTGCCCACTGGGAAGAAGCTGATCCT  
GCAACAAGAGAGTCTGAGGTTAGACCAGGAGTGGAACCTTCTTAGCAGTG  
GGCCTGGGGTGGTGCTGGGCAGGGTGAGGTATGTTGGGTGGAGGGCCGGG  
GAGGGTCTGGAACCTGCCCTCCTGCCTCTCCCATTCCTGCATGTACCCT  
TTCTTTCTATATGACATCTGCCACTCACCCAGCCATTCCTTGACCCAG  
TCTGGGCCCGGGGGCCAGGTCTCACCCAAGCTCTTTTTCTTTTTCTTTT  
TTTATTTTTTTGAGACAGGGTCTCGCTCTGTGCGCCAGGCTGCTGTGCAA  
TGGCGTGATCACAGCTCACTGCTGTCTCTGCCTCCCAGGTTCAAGTGATT

1588-1747

(1)

### **FIGURE 6 (cont'd)**

Year	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	

## FIGURE 6 (cont'd)

ACAGTAGCTGGCATTGAAGAGGGTCAGGTCTGGATTTCGTTGTCTCTGACG  
CTGGAGAGACAAGAAAGTTCTTGAGTTATGCCACTCAAAGTCAAATGTCA  
AAGATCAAAGAGACCGTCAATCATCTGGGGTCATGATTCATATGAAATTA  
AGTCATAAATATGTAACCTTGGAGGTTTCGGGATTGTAGTACAGGTCCGGTG  
AGGGGCAGGGGTATTGACATGGATGGGCCACATCCAGGGAAGAGGGACGT  
GGCCTCAAAGTGGGGAGATTTAGGGGACCCTGCAGCACGCATGTTCTCTC  
TCCAGACCCATTCCCGGATCTGCTCCAGTGCCTCAACCTCTCCATCGTCT<sup>4806-4939</sup>  
CCCATGCCACCTGCCATGGTGTGTATCCCGGGAGAATCACGAGCAACATG (3)  
GTGTGTGCAGGCGGGCGTCCCGGGGCAGGATGCCTGCCAGGTGAGCCAGTG

00127366:040199

**THIS PAGE BLANK (USPTO)**